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Functions of the nervous system are accompanied at the cellular level by
changes in gene expression, regulated by transcription factors and epigenetic
mechanisms, such as histone modifications and DNA methylation, that are
frequently altered in neurological disorders. 5-hydroxymethylcytosine (5hmC), a
recently identified DNA base derived from 5-methylcytosine, accounts for ~40%
of modified cytosines in the neuronal genomes, suggesting that 5hmC is a stable
epigenetic mark and its interpretation in the nervous system may differ from the
other tissues. This hypothesis was supported by the recent findings showing that
5hmC is enriched over the bodies of active genes within euchromatin in a cellspecific manner. In the first part of this study, we identify the methyl-CpG binding
protein 2 (MeCP2) as the major reader of this activation mark and demonstrate
that MeCP2 is the only methyl-CpG binding domain (MBD) protein that binds
5hmC and, 5mC, with high affinity. We reveal strong preferential inhibition of
MeCP2 affinity to 5hmC by a Rett-syndrome-causing mutation, R133C. We then
show that MeCP2 recognizes 5hmC and 5mC within CpA context. Modified CpAs
were recently shown to exist in embryonic stem and neuronal cells, where it

localizes to actively transcribed gene bodies. Together these data support a
model where 5hmC and MeCP2 formulate a cell-specific epigenetic mechanism
for establishing active chromatin states that facilitate gene expression. This is
supported by our observation of reduced chromatin accessibility of 5hmC
containing loci in the absence of MeCP2.
In the second part of the study, we discover a complex in the brain nuclear
extract that assembles specifically in the presence of 5hmC. We purify and
identify components of this complex: the purine-rich element binding protein (Pur)
α and β, which are required for the proper development of neuronal cell types.
We verify the increased affinity of recombinant Purα and Purβ to 5hmC and
support a binding mechanism where they separate two strands of DNA and
recognize specific sequences. These findings offer a previously unknown
function for Pur proteins via binding to 5hmC.
This study presents new decoders of a novel epigenetic mark, 5hmC, that is
effectively and differentially employed in the brain. Unlike previous studies, we
introduce readers of 5hmC as a stable activation mark. In addition, by
mechanistic characterization of our model we link 5hmC to an autism spectrum
disorder and offer a new avenue toward investigation of its pathophysiology.
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Chapter I.
Introduction
I.I. Prologue: from brain to chromatin
!

Understanding how the brain works is one of the most exciting scientific

quests of our age. The study of the nervous system started over a century ago
with the identification of individual neuron as its “absolutely autonomous unit” by
Ramón y Cajal (Ramon y Cajal 1899; Ramón y Cajal 1917). We now know that
the mammalian central nervous system (CNS) is a highly sophisticated network
made of hundreds of distinct classes of neurons and glia, nourished by blood
vessels (Jones, Stone et al. 2011; Reid 2012).
The basic function of a neuron is to receive a chemical/physical signal at its
dendritic extensions or its cell body; convert it into an electrical signal by
manipulating ion gradient across its membrane; and transmit the so-called action
potential to its destination on the axon where it is converted into a chemical
signal by the release of signaling molecules for its target cell (Kandel, Schwartz
et al. 2000). Neurons can be classified into hundreds of types, each with unique
sets of functions and distinct anatomical, molecular and electrochemical profiles
(Masland 2004; Lichtman, Livet et al. 2008). Glia, which far outnumber the
neurons (Kandel, Schwartz et al. 2000), are housekeepers, insulators and nurses
of the neurons. Some are also thought to participate in neurotransmission and to
surveil, sculpt and modulate synaptic connections (Allen and Barres 2009;
Graeber 2010).
1

The diversity of cell types in the CNS and their complex interconnectivity is
established by their unique collection of expressed genes (Nelson, Sugino et al.
2006). Since the genomic information is identical in every cell, organisms use
transcription factors aided by “epigenetic”, or “outside conventional genetic”,
mechanisms that formulate these characteristic gene expression profiles
(Jaenisch and Bird 2003). Epigenetic mechanisms include changes in the
chemical, physical and topological characteristics of the chromatin, where the
genomic information resides. These changes cause a discrepancy in the nuclear
architecture that is readily visible under microscope: not only in the aggregation
pattern of chromatin; but also in the structure of the nuclear envelope, in the
distribution of nuclear pores and nuclear bodies. (Takizawa and Meshorer 2008).
Chromatin is a three-dimensional structure, made of DNA, histones and other
architectural factors. The most obvious form of its structural organization is the
compartmentalization into “euchromatin” and “heterochromatin”, as first
described almost a century ago (Heitz 1928). Heterochromatin encompasses
highly condensed regions where the genomic material is inaccessible and
therefore “silent”; whereas euchromatin appears decondensed and contains
actively expressed regions of genetic material. For instance, Purkinje cells (PCs),
which are among the largest cells in the brain, have large nuclei and store only
10% of their DNA in heterochromatin in the center of their nucleus (Fig 1.1). In
contrast, the nuclei of granule cells (GCs) are small, compact and display ~64%
of their genome in large aggregates heterochromatin that are scattered in the
nuclear periphery (Palay and Chan-Palay 1974; Lafarga, Berciano et al. 1991).

2

3

I.II. Chromatin: the nucleoprotein
!

Historical perspectives, which considered chromatin to be a static,

unchanging entity, have been replaced by the current appreciation of its modular,
complex and highly plastic nature. The basic building unit of chromatin is the
nucleosome, which is formed by wrapping ~146 base pairs (bp) of DNA around a
histone core, which consists of two copies of each histone proteins, H2A, H2B,
H3 and H4 (Fig 1.2) (Hamon and Cossart 2008; Takizawa and Meshorer 2008).
Each histone protein contains a globular part and an unstructured N-terminal tail
that protrudes from the nucleosome (Luger, Maeder et al. 1997; Andrews and
Luger 2011). These tails can accommodate a variety of chemical modifications
that can influence local protein composition, arrangement of nucleosomal arrays
and histone-DNA interactions. The combinatorial nature of histone modifications
reveals a “histone code” that defines chromatin states (Jenuwein and Allis 2001;
Andrews and Luger 2011). For example, euchromatin is normally marked with
histone H3 trimethylated on lysine 4 (H3K4me3) and acetylated on lysine 9
(H3K9ac); while H3K9me3 and H4K20me3 are concentrated in constitutive
heterochromatin and H3K27me3 in facultative heterochromatin. Global structure
of the chromatin is also regulated by other proteins, such as chromatin
remodeling enzymes, transcriptional activators and repressors, architectural
proteins, and the “linker histone”, H1, that binds the “linker DNA” bridging two
adjacent nucleosomes, (Misteli 2001).

4
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I.III. Chromatin: nucleic acid modifications
!

Chromatin states are largely established by chromatin-associated factors;

however they also can be influenced at base resolution by direct chemical
modifications of DNA. Although nucleic acid of various organisms accommodates
over 100 modified bases, in the mammalian DNA, the principle DNA modification
seemed to be the methylation of cytosines (Cs) in symmetric CpG dinucleotides
(5-methylcytosine, 5mC or “the fifth base”) (Bird 2002; Ratel, Ravanat et al.
2006). Today, non-CpG methylation (Ramsahoye, Biniszkiewicz et al. 2000;
Pastor, Pape et al. 2011) and oxidation products of 5mC, primarily 5hydroxymethylcytosine (5hmC or “the sixth base”) (Kriaucionis and Heintz 2009;
Tahiliani, Koh et al. 2009; Ito, Shen et al. 2011), are also accepted as major
mammalian DNA modifications. Other epigenetic mechanisms at the nucleic acid
level include the occurrence of these modifications in the mitochondria (Pollack,
Kasir et al. 1984; Dzitoyeva, Chen et al. 2012) and also a complex realm of noncoding RNAs (Mehler and Mattick 2007; Satterlee, Barbee et al. 2007).

I.IV. 5mC: discovery, genomic distribution and function
!

5mC entered the scientific vocabulary almost a century ago (Johnson and

Coghill 1925) and its presence in the mammalian genome was discovered 25
years later (Wyatt 1950). It also is found in the genome of other vertebrates,
flowering plants, invertebrates, protists, fungi and bacteria (Goll and Bestor
2005). Interestingly, the invertebrate-vertebrate boundary marks a distinctive

6

evolutionary shift from a fractional to a global methylation pattern, where almost
all gene bodies are methylated in vertebrates (Tweedie, Charlton et al. 1997).
Eukaryotic DNA methylation is now recognized to be a chief contributor to the
silent chromatin state and inhibition of gene expression (Jaenisch and Bird 2003;
Ooi, O'Donnell et al. 2009). Strong evidence for the silencing role of 5mC comes
from its high levels in the heterochromatin and in the repeat elements that are
thus stabilized (Doskocil and Sorm 1962; Keshet, Lieman-Hurwitz et al. 1986).
Another major manifestation of this role is the X chromosome inactivation, where
the silent X is invariably hypermethylated (Riggs 1975; Heard, Clerc et al. 1997;
Walsh, Chaillet et al. 1998). In the early studies, artificially methylated transgenes
inserted into mouse cells were repressed (Stein, Razin et al. 1982). Conversely,
chemical inhibition of methylation reverses the silencing of previously methylated
genes (Groudine, Eisenman et al. 1981; Mohandas, Sparkes et al. 1981).
In silent chromatin, 5mC is found as a permanent mark; whereas differentially
methylated regions (DMRs) are regulated in a cell-specific manner (Song, Smith
et al. 2005; Hahn, Wu et al. 2011; Lister, Pelizzola et al. 2009) in concert with the
repressive histone signal H3K9me3. Accordingly, activating histone marks, such
as H3K27me3, H3K4me and H2A.Z variant, are excluded from methylated
regions (Meissner, Mikkelsen et al. 2008; Zilberman, Coleman-Derr et al. 2008;
Laurent, Wong et al. 2010; Coleman-Derr and Zilberman 2012). In many cancer
cells, aberrant methylation patterns are frequently observed (Ting, McGarvey et
al. 2006; Irizarry, Ladd-Acosta et al. 2009).

7

I.V. CpG dinucleotide and beyond
!

In mammals, the predominant form of DNA methylation occurs

symmetrically within CpG dinucleotides and it comprises 70-80% of these
dinucleotides (Bird, Taggart et al. 1985). Interestingly, CpG-rich regions (CpG
islands or CGIs), which are found within promoter regions of 70% of human
genes, contain very low amounts of methylation (Bird, Taggart et al. 1985;
Saxonov, Berg et al. 2006). However, these may become methylated if the gene
needs to be repressed in the course of development (Li, Beard et al. 1993) or
differentiation (Song, Smith et al. 2005). Cytosine methylation is also a prominent
cause of mutations. In humans, the mutation rate from 5mC to thymine (T) is
10-50 fold higher than other transitions (Duncan and Miller 1980), causing the
CpG dinucleotide to be present only at 20% of its expected frequency (Sved and
Bird 1990). The deamination of one 5mC in a CpG dinucleotide generates a
5mCpG‧TpG mismatch (Wiebauer and Jiricny 1989), which can then be
“corrected” to a CpA by thymine DNA glycosylase (TDG) (Neddermann, Gallinari
et al. 1996).
Until recently, the methylation studies were focused on the CpG dinucleotide but
newer studies revealed that non-CpG methylation, primarily CpA methylation,
constitutes 20-25% of genome-wide methylation in mammalian pluripotent and
differentiated cells (Ramsahoye, Biniszkiewicz et al. 2000; Lister, Pelizzola et al.
2009; Laurent, Wong et al. 2010). CpA methylation is reduced at promoters but
highly enriched in the gene bodies exhibiting strong correlation with gene
expression, whereas no such correlation is observed for CpG methylation (Lister,
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Pelizzola et al. 2009; Laurent, Wong et al. 2010). Non-CpG methylation in gene
bodies is asymmetrical almost at all times, even in CHG context, and is
significantly enriched on the antisense strand. The expanded context of non-CpG
context is TACA(A/T), with a periodicity of 8-10 bp between modified Cs
corresponding to a single turn of the DNA helix (Lister, Pelizzola et al. 2009).
Thus a pattern, where methyl groups aligned linearly on the DNA strand,
becomes obvious and may be definitive in coordination of methylation-specific
proteins.

I.VI. Dnmts: enzymes in the making of 5mC
!

5mC is generated by the covalent addition of a methyl group from S-

adenosyl-L-methionine (SAM) to the 5 position of cytosine by a DNA
methyltransferase, Dnmt (Fig 1.3) (Santi, Garrett et al. 1983; Bestor 2000; Lin
2011). The originally cloned Dnmt was the “maintenance” methyltransferase,
Dnmt1, that methylates hemimethylated CpG dinucleotides during replication
(Bestor and Ingram 1983). Later, de novo methyltransferases, Dnmt3a and
Dnmt3b, were discovered which can methylate both unmethylated and
hemimethylated target sequences (Bestor and Ingram 1983; Bestor 1988; Mund,
Musch et al. 2004). The last family member, Dnmt2, has only weak activity
toward DNA and is now accepted to be an RNA methylase (Okano, Xie et al.
1998; Mund, Musch et al. 2004).

9
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Dnmt1 is recruited to replication fork via ubiquitin-like plant homeodomain and
RING finger domain 1 (Uhrf1) that recognizes hemimethylated DNA, whereas de
novo methyltransferases bind DNA directly independent of its modification status
(Bostick, Kim et al. 2007; Sharif, Muto et al. 2007). Dnmts are frequently found
associated with heterochromatin regions in a cell-cycle-independent manner
(Bachman, Rountree et al. 2001; Hermann, Goyal et al. 2004). Non-CpG
methylation is thought to be carried out by Dnmt3a (Ramsahoye, Biniszkiewicz et
al. 2000; Mund, Musch et al. 2004; Laurent, Wong et al. 2010; Arand, Spieler et
al. 2012), although a role for Dnmt1 was also proposed based on the inheritance
of non-CpG methylome (Grandjean, Yaman et al. 2007).
Dnmt3b is expressed within a narrow window during embryogenesis, whereas
Dnmt1 and Dnmt3a are present throughout life (Okano, Bell et al. 1999). The
absence of Dnmts can lead to global DNA hypomethylation, chromosomal
instability and aberrant cell-cycle progression, although they are not required for
embryonic stem (ES) cell integrity or self-renewal (Tsumura, Hayakawa et al.
2006). Nevertheless, the deletion of Dnmt1 or Dnmt3b in mice results in
embryonic lethality (Li, Bestor et al. 1992), while Dnmt3a

-/-

mice survive up to 4

weeks with normal methylation in heterochromatic regions (Okano, Bell et al.
1999) and Dnmt2

-/-

does not have a phenotype (Okano, Xie et al. 1998).

Mutations in the DNMT3B gene has been linked to instability facial anomalies
(ICF) syndrome in humans (Okano, Bell et al. 1999).

11

I.VII. Dnmts in the brain
!

The majority of DNA methylation mechanisms have been characterized in

ES cells yet their influence on the CNS remains unclear. For instance, multiple
isoforms of de novo methyltransferases are expressed in ES cells, but only fulllength variant of Dnmt3a is found at high levels and in diffuse pattern in neurons
(Feng, Chang et al. 2005; Nguyen, Meletis et al. 2007), suggesting that
euchromatic de novo methylation might be specifically needed for neuronal
functions. Indeed, nonpromoter methylation by Dnmt3a promotes transcription of
neural genes (Wu, Coskun et al. 2010) and regulates cellular and behavioral
plasticity in response to emotional stimuli in mice (LaPlant, Vialou et al. 2010).
Moreover, after fear conditioning, Dnmt3a levels double whereas Dnmt1 level is
unchanged, indicative of an interplay between neuronal activity and euchromatic,
nonpromoter, Dnmt3a-mediated methylation (Miller and Sweatt 2007).
The lethality of the Dnmt-knockouts in the early stages of life necessitated
alternative approaches for the study of methylation in postmitotic cells. Initially,
pharmacological Dnmt inhibitors were used, such as RG108 (Brueckner, Garcia
Boy et al. 2005), a competitive Dnmt1 inhibitor, or 5-azacytidine (Creusot, Acs et
al. 1982; Miller and Sweatt 2007) and zebularine (Levenson, Roth et al. 2006;
Miller, Gavin et al. 2010). Since the latter two chemicals are incorporated into the
DNA after replication, in non-dividing cells they did not pan out to be useful.
In later studies, a brain-restricted knockout of Dnmt1 resulted in an estimated
50% loss of methylation and produced mutant neurons and glia (Fan, Beard et al.
2001; Golshani, Hutnick et al. 2005). However when Dnmt1 was inactivated in
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the adult brain, global DNA methylation and cell survival were unaffected (Fan,
Beard et al. 2001). Deletion of Dnmt3a in the developing CNS leads to
neuromuscular defects and shortens lifespan (Nguyen, Meletis et al. 2007),
whereas in its postnatal ablation in excitatory neurons long-term plasticity,
learning and memory are impaired, by upregulation of immune genes (Feng,
Zhou et al. 2010) that are considered breaks of synaptic plasticity (Shatz 2009).

I.VIII. MBDs: 5mC-binding proteins
!

The widely accepted role for 5mC is to displace some DNA binding

proteins and to recruit methylation specific proteins (Watt and Molloy 1988; Klose
and Bird 2004). The first “activity that could bind methylated DNA in solution” was
methyl-CpG binding protein (MeCP) (Meehan, Lewis et al. 1989), that turned out
to be a multiprotein complex, MeCP1 (Ng, Zhang et al. 1999; Feng and Zhang
2001). In contrast, another such activity, MeCP2, was a single polypeptide
(Lewis, Meehan et al. 1992) with an 80 amino acid methyl-CpG binding domain
(MBD), which is necessary and sufficient for recognition of 5mC (Nan, Meehan et
al. 1993; Nan, Tate et al. 1996; Nan, Campoy et al. 1997). A database search
revealed four additional proteins that contain the consensus MBD sequence:
MBD1 through MBD4 (Hendrich and Bird 1998; Dhasarathy and Wade 2008).
Among the MBD family of proteins, MBD1 acts as a transcriptional repressor by
recruiting histone deacetylases (HDACs) upon binding both to 5mC with its MBD
and to unmodified DNA with one of its three zinc-coordinating CXXC domains
(Fujita, Shimotake et al. 2000; Jorgensen, Ben-Porath et al. 2004). MBD2 and
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MBD3 share 70% sequence identity and are thought to have arisen through gene
duplication (Hendrich and Bird 1998; Hendrich and Tweedie 2003). MBD3 is the
only MBD protein that does not recognize 5mC (Zhang, Ng et al. 1999) due to
two amino acid substitutions in the MBD (Fraga, Ballestar et al. 2003). It is a core
component of nucleosome remodeling and histone deacetylase repressor
(NuRD) complex (Saito and Ishikawa 2002), which is recruited to DNA by MBD2
(Feng and Zhang 2001). Together they make up the MeCP1 complex. MBD4
appears to play a key role in DNA repair, by preferentially binding to and
processing a 5mCpG‧TpG mispair with its glycosylase domain (Hendrich,
Hardeland et al. 1999).
A recent comparative analysis identified six additional proteins that contain an
MBD: MBD5, MBD6, BAZ2A, BAZ2B, SETDB1 and SETDB2 (Roloff, Ropers et
al. 2003). Most of these proteins do not show specificity for methylated DNA
except SETDB1 (Gou, Rubalcava et al. 2010), and their functions vary (Hendrich
and Tweedie 2003; Laget, Joulie et al. 2010). A novel 5mC binding protein,
Kaiso, lacks MBD, but recognizes 5mC through zinc finger domains, and
mediates repression by associating with the NCoR complex (Hendrich and Bird
1998; Prokhortchouk, Hendrich et al. 2001; Yoon, Chan et al. 2003).

I.IX. MBDs in the brain
!

The phenotypic deficits in Mbd1

-/-

mice are restricted to CNS, specifically

in learning, memory and plasticity, due to reduced neuronal differentiation and
increased genomic instability (Zhao, Ueba et al. 2003). Mbd2
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-/-

mice show minor

behavioral deficits whereas deletion of Mbd3 is embryonic lethal (Hendrich, Guy
et al. 2001). A role for MBD3 in the neuronal development was suggested since
its levels are regulated throughout developing brain, unlike MBD2 which displays
minimal expression in the embryonic brain (Jung, Zhang et al. 2003). There is
clinical evidence that links MBD5 to mental disorders (Williams, Mullegama et al.
2010; Noh and Graham Jr 2012), however the mechanism is still unclear.
Although Setdb1

-/-

mice seem normal (Jiang, Matevossian et al. 2011) and the

Setdb1 gene is expressed at very low levels in the CNS, its histone
methyltransferase activity might be required for proper CNS functioning (Ryu,
Lee et al. 2006; Jiang, Matevossian et al. 2011). Finally, despite the fact that the
X-linked Kaiso gene is highly expressed in the brain, it was not linked to CNS
dysfunction (Della Ragione, Tiunova et al. 2006; Prokhortchouk, Sansom et al.
2006).

I.X. MBDs: the curious case of MeCP2
!

MeCP2 constitutes a unique case within the neuronal epigenetic

mechanisms, because of its abundance, enigmatic functions and the clinical
manifestation of its dysfunction. MeCP2 is present in all vertebrates and is in fact
a “vertebrate invention” (Bird, A., personal communication). The expression of
MeCP2 in mice is low at birth, increases greatly in the first three weeks and
plateaus when it is expressed near nucleosome levels in the brain (Kishi and
Macklis 2004; Skene, Illingworth et al. 2010). It is also expressed to some extent
in the lung and spleen (Shahbazian, Young et al. 2002).
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• Structure and disorder in MeCP2

The full-length human MeCP2 is 60% unstructured, and its secondary structure is
stabilized upon binding to DNA or proteins (Adams, McBryant et al. 2007; Ghosh,
Nikitina et al. 2010). The X-ray structure of MeCP2 MBD with a 5mCpGcontaining DNA (Wakefield, Smith et al. 1999) revealed that 5mC and MBD make
multiple contacts, several of which are maintained by immobilized water
molecules in the major groove of the double helix (Ho, McNae et al. 2008).
Although MeCP2 exists strictly as a monomer in solution (Ghosh, HorowitzScherer et al. 2010), it can form clusters upon binding to methylated DNA
(Nikitina, Ghosh et al. 2007). MeCP2 affinity to DNA increases with the length of
the DNA independent of methylation (Nan, Hou et al. 2007).
In addition to MBD, MeCP2 also contains a basic N-terminal domain with two
consensus A/T-hook motifs which bind the minor groove of A/T-rich duplex DNA
(Adams, McBryant et al. 2007), and a C-terminal TRD domain that can interact
with several factors, including transcription repressors, HDACs, NCoR, mSin3a
and CoREST; transcription activators, YY1, YB1, CREB and Brahma; and
heterochromatin associated factors, HP1, Dnmt1 and Atrx (Nan, Ng et al. 1998;
Kokura, Kaul et al. 2001; Fuks, Hurd et al. 2003; Harikrishnan, Chow et al. 2005;
Young, Hong et al. 2005; Agarwal, Hardt et al. 2007; Chahrour, Jung et al. 2008;
Forlani, Giarda et al. 2010). The functions of these interactions remain elusive.
• MeCP2: a transcriptional repressor, or activator?

Several biochemical and chromatin immunoprecipitation (ChIP) experiments
showed that MeCP2 avidly binds methylated DNA (Lewis, Meehan et al. 1992;
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Gregory, Randall et al. 2001; Skene, Illingworth et al. 2010), which is associated
with gene silencing. The direct involvement of MeCP2 in transcriptional
repression by a methylation dependent mechanism was demonstrated in cell
culture studies (Boyes and Bird 1991; Nan, Campoy et al. 1997; El-Osta,
Kantharidis et al. 2002) and later in reconstituted systems in Drosophila
melanogaster, which lacks genomic methylation (Kudo 1998). In cortical cultures
MeCP2 can associate with some neural genes, such as Bdnf (Chen, Chang et al.
2003; Kernohan, Jiang et al. 2010), and this interaction is lost upon stimulation
with KCl (Harikrishnan, Bayles et al. 2010; Tian, Marini et al. 2010), leading to
increased expression (Martinowich, Hattori et al. 2003).
The widely accepted role of MeCP2 as a transcriptional repressor was
challenged with the availability of Mecp2

-/-

mice: First, a brain-restricted deletion

of Mecp2 resulted only in subtle changes in gene expression (Tudor, Akbarian et
al. 2002; Jordan, Li et al. 2007) and the search for genes that are repressed by
MeCP2, has so far identified only a few targets (Nuber, Kriaucionis et al. 2005;
Kriaucionis, Paterson et al. 2006; Jordan, Li et al. 2007). Later analyses of gene
expression in hypothalami and cerebella of Mecp2-deficient and Mecp2overexpressing mice, revealed that the majority of genes were activated by
MeCP2 (Chahrour, Jung et al. 2008; Ben-Shachar, Chahrour et al. 2009). Some
groups also reported MeCP2-dependent changes in gene splicing (Young, Hong
et al. 2005), microRNA profiles (Urdinguio, Fernandez et al. 2010), and
transcription of repetitive elements (Skene, Illingworth et al. 2010). Thus a more
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complex role for MeCP2 was proposed, where it dampens transcriptional noise
as a buffer and/or regulates transcription depending on the molecular context.
• Where is MeCP2?

The early studies showed that MeCP2 localizes in heterochromatic foci (Hendrich
and Bird 1998), that it can stably associate with nucleosomes with methylated
DNA and linker DNA (Chandler, Guschin et al. 1999; Yang, van der Woerd et al.
2011), and that it can facilitate chromatin compaction (Georgel, Horowitz-Scherer
et al. 2003; Nikitina, Ghosh et al. 2007; Nikitina, Shi et al. 2007). In addition,
absence of Mecp2 caused a normally silent chromatin loop to shift into an active
chromatin state (Horike, Cai et al. 2005). Hence an alternative/additional role was
advocated for MeCP2 in the management of the higher order chromatin
landscape.
To the contrary, in two independent genome-wide analyses, MeCP2 was found
broadly distributed over the genome and not localized at discrete sites, such as
heterochromatic regions or promoters of repressed genes (Yasui, Peddada et al.
2007; Skene, Illingworth et al. 2010). Yet if MeCP2 covers the whole genome and
its primary role is the organization of heterochromatin, then one would wonder
why not all genome is condensed. Indeed, upon reexamination of nuclear
staining of MeCP2 (LaSalle and Gerald 2004; Nan, Hou et al. 2007), it is evident
that at heterochromatic foci MeCP2 is dense, as is DNA. The hypothesis that
MeCP2 broadly covers the genome gained more support as more evidence
came to light. For instance, in the absence of both Mecp2 and Dnmts, the
chromatin structure undergoes global changes, including altered histone
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acetylation and doubling of histone H1 (Nan, Campoy et al. 1997; Shahbazian,
Young et al. 2002; Skene, Illingworth et al. 2010), not only in neurons but also in
glia (Ballas, Lioy et al. 2009). This is complimentary to the observation that
histone H1 levels in neurons are 50% less than in other cell types (Pearson,
Bates et al. 1984) and that MeCP2 can compete with H1 on nucleosomes
containing methylated DNA (Ghosh, Horowitz-Scherer et al. 2010). Together
these results imply a histone H1-like role for MeCP2.
In a recent study, a population of MeCP2 was found in chromatin regions that
contain high levels of nucleosome and a second loosely-bound population in
euchromatin. This second population was unique to the brain and absent in other
tissues, suggesting a tissue-specific functional compartmentalization of MeCP2
(Thambirajah, Ng et al. 2011). An earlier chromatin fractionation study from
cultured human cells showed that the majority of MeCP2 is present in the more
nuclease-accessible, active regions of chromatin, while a small portion was
associated with heterochromatin (Ishibashi, Thambirajah et al. 2008). Intriguingly,
in the absence of Mecp2, the size of neuronal nuclei fails to increase at normal
rates during differentiation and transcription is attenuated (Yazdani, Deogracias
et al. 2012), both indicative of involvement of MeCP2 in the configuration of
euchromatin state. The association of MeCP2 with active genes and active
chromatin may seem to contradict its widely accepted role in repression and
heterochromatin. However they can also simply be the manifestations of a
dynamic, temporally dependent and activity-dependent function (Metivier, Gallais
et al. 2008).
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• Rett Syndrome: A direct link to MeCP2 dysfunction

It was not too long after discovery of MeCP2 that it was directly linked to Rett
Syndrome (RTT) (Amir, Van den Veyver et al. 1999). Being an X-linked gene;
mutations of MECP2 affect males much more severely than girls, which exhibit
mosaicism in heterozygocity after one X-chromosome is inactivated during
dosage compensation (Adler, Quaderi et al. 1999). In line with the expression
pattern of MeCP2, the symptoms of RTT arise only after 6-18 moths of age in
girls: loss of speech, loss of purposeful hand use, stereotypical movements,
seizures, mental retardation and hyperventilation. Only few boys are diagnosed
as they die within two years of birth (Hagberg, J et al. 1983). In postmortem brain
tissue from RTT patients, lower spine density in hippocampal pyramidal neurons
was observed (Chapleau, Calfa et al. 2009). Neurons, derived from induced
pluripotent stem cells generated from RTT patientsʼ fibroblasts, had reduced
spine density, smaller cell body and electrophysiological defects (Marchetto,
Carromeu et al. 2010; Cheung, Horvath et al. 2011).
Several deletions and mutants of MeCP2 have been created in mice (Chen,
Akbarian et al. 2001; Guy, Hendrich et al. 2001; Pelka, Watson et al. 2006).
Although heterozygous females acquire some phenotypes only in older ages;
homozygous females and hemizygous males exhibit RTT symptoms at 5 weeks
and die between 6 and 12 weeks. (Guy, Hendrich et al. 2001). Brain-specific
deletion of Mecp2 during or after development results in full knockout phenotype
(Chen, Akbarian et al. 2001; Nguyen, Du et al. 2012), as mice carrying MeCP2
with RTT-causing mutations (Shahbazian, Young et al. 2002; Lawson-Yuen, Liu
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et al. 2007). In these mice, the gross brain architecture is normal, indicating that
MeCP2 is not required for neurodevelopment. However smaller and densely
packed nuclei and cell bodies were obvious. The spine number and dendritic
complexity was also reduced (Na and Monteggia 2011), in agreement with a cell
culture study, showing loss of Mecp2 leads to reduction in synapse numbers,
which is reversed upon gain of Mecp2 (Chao, Zoghbi et al. 2007). In the absence
of MeCP2, inhibitory activity increases and excitatory activity decreases resulting
in cortical dysfunction (Dani, Chang et al. 2005).
Overexpression of Mecp2 only by two-fold initially results in enhanced learning
and plasticity (Collins, Levenson et al. 2004). At 20 weeks of age neurological
symptoms start to appear and mice have shorter life span. Serine-421 (S421) of
MeCP2 was initially identified as an activity induced phosphorylation site that
displaces MeCP2 from DNA (Zhou, Hong et al. 2006); however a S421A
mutation changed neither the genome-wide binding of MeCP2 in vivo nor the
expression of specific genes. The mice carrying these mutations exhibited
defects in synapse development in cortical pyramidal neurons and mild
behavioral abnormalities (Cohen, Gabel et al. 2011). In another study, the S421A/
S424A double mutants exhibited overexpression phenotypes (Li, Zhong et al.
2011). S80 is ubiquitously phosphorylated, but this is lost upon neural stimulation
(Tao, Hu et al. 2009). Mice carrying S80A mutation show mild phenotypes, and
DNA binding of MeCP2 is attenuated.
Deletion of Mecp2 in inhibitory (Chao, Chen et al. 2010) and excitatory (Samaco,
Hogart et al. 2005) neurons, as well as in confined regions in the brain
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(Bissonnette and Knopp 2006; Gemelli, Berton et al. 2006; Fyffe, Neul et al.
2008), mimics various aspects of the disease in mice. Complementary to these
results, full reactivation of Mecp2 in its original levels and partial reactivation in
neuron subpopulations reverses some or all phenotypes (Collins, Levenson et al.
2004; Luikenhuis, Giacometti et al. 2004; Giacometti, Luikenhuis et al. 2007).
Mecp2

-/-

astrocytes cause abnormalities in neurons (Ballas, Lioy et al. 2009;

Maezawa, Swanberg et al. 2009), and reactivation of Mecp2 in astrocytes in null
mice reverses majority of the disease phenotypes (Lioy, Garg et al. 2012).
Interestingly, hippocampal neurons treated with conditioned medium obtained
from Mecp2-null microglia, which release five-fold higher glutamate, develop
abnormally (Maezawa and Jin 2010); and transplantation of WT myeloid cells
into Mecp2 -/- mice arrests major symptoms of RTT (Derecki, Cronk et al. 2012).
In summary, MeCP2 and RTT present a particular case of the epigenetics of the
brain that is fundamentally different from other tissues. Here, subtle changes at
the molecular level have severe consequences. Now, the addition of 5hmC to the
vocabulary of brain epigenetics may provide more insight into the complexity of
the mechanisms that sustain the CNS.

I.XI. 5hmC: discovery, genomic distribution and function
!

The existence of 5hmC in the mammalian genome was re-discovered

during a comparative study of the genomic 5mC content between large and
decondensed PC nuclei and compact GC nuclei (Fig 1.1), 60 years after its first
discovery in T2 bacteriophages (Wyatt and Cohen 1952; Warren 1980;
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Kriaucionis and Heintz 2009). Its presence in the mammalian brain was initially
suggested (Penn, Suwalski et al. 1972), but this was not reproduced by others
(Kothari and Shankar 1976; Gommers-Ampt and Borst 1995).
5hmC levels in the brain range from 0.4 to 0.65 % of all Cs, whereas kidney, lung
and muscle tissue exhibit “medium” levels, and finally lowest levels are detected
in the spleen, liver and testis. In contrast, 5mC levels are constant at 4-5 % in a
variety of tissues (Globisch, Münzel et al. 2010). The change in the amount of
5mC between cell populations was complementary to the levels of 5hmC
suggesting that 5mC and 5hmC may be derived from each other (Kriaucionis and
Heintz 2009).
5hmC is invariably enriched on euchromatin regardless of the cell type or
developmental stage tested (Ficz, Branco et al. 2011; Szulwach, Li et al. 2011).
For instance, on metaphase chromosomes, 5hmC is located on chromosome
arms but depleted on centromers that contain high levels of 5mC (Szulwach, Li et
al. 2011). 5hmC levels are highest within globally decondensed nuclei enriched in
active chromatin, such as those of ES cells or PCs (Meshorer and Misteli 2006;
Kriaucionis and Heintz 2009; Tahiliani, Koh et al. 2009). The localization of 5hmC
within the “on” state of chromatin implies that it may be involved in gene
activation. Indeed gene bodies, promoters, transcription start sites (TSSs) and
enhancer elements of active genes in ES cells have elevated levels of 5hmC,
that strongly tracks with active enhancer marks, p300, H3K4me1, H3K4me2,
H3K18ac and H3K27ac, and is mostly excluded from heterochromatin marks
H3K27me3 (Ficz, Branco et al. 2011; Pastor, Pape et al. 2011; Stroud, Feng et al.
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2011; Szulwach, Li et al. 2011; Wu, D'Alessio et al. 2011; Booth, Branco et al.
2012; Yu, Hon et al. 2012). Intriguingly, extensive strand-bias was detected in
methylomes and hydroxymethylomes of ES cells largely in non-CpG context
(Ficz, Branco et al. 2011), which increased in the absence of Uhrf1,Tet1 and Tet2;
suggesting that Dnmt3a or Dnmt3b with Tet3, or other putative enzymes might be
required for asymmetric hydroxymethylation.
In tissue samples 5hmC levels correlate with the differentiation state of cells,
increasing toward terminally differentiated layers in hierarchically organized
tissues and mainly enriched in gene bodies (Münzel, Globisch et al. 2010;
Haffner, Chaux et al. 2011; Song, Szulwach et al. 2011; Orr, Haffner et al. 2012).
Aberrant hydroxymethylation patterns are observed in both imprinting disorders
and cancer (Haffner, Chaux et al. 2011).
The function of 5hmC still remains unclear: an intermediate in active or passive
demethylation pathways, or a bona fide epigenetic mark. It is now widely
accepted that 5hmC is passively demethylated in dividing cells, since Dnmt1
does not recognize hemihydroxymethylated DNA as substrate (Valinluck and
Sowers 2007; Hashimoto, Liu et al. 2012). However Uhrf1, which recruits Dnmt1
onto hemimethylated DNA, can bind hemi- and fully hydroxymethylated CpG
sites with similar affinity (Sharif, Muto et al. 2007; Frauer, Hoffmann et al. 2011).
Therefore, it should be investigated whether a Uhrf1-mediated mechanism
maintains hemihydroxymethylated sites over cell divisions in vivo.
A second proposed role for 5hmC is an intermediate in active demethylation
events, such as the reprogramming of methylome during embryogenesis, where
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global methylation patterns are erased and a wave of de novo methylation
follows (Mayer, Niveleau et al. 2000; Hajkova, Erhardt et al. 2002; Chen, Ueda et
al. 2003; Hackett, Zylicz et al. 2012). This way a pluripotent state can be
established in the zygote and then again in developing primordial germ cells
(Reik, Dean et al. 2001). Within hours of fertilization, the male genome is stripped
of methylation at a faster rate than cell division (Oswald, Engemann et al. 2000).
Several groups have proposed that this process involves active demethylation
mechanisms via DNA glycosylases, other putative DNA decarboxylases (Wu and
Zhang 2010; Cortellino, Xu et al. 2011; He, Li et al. 2011; Inoue and Zhang 2011;
Maiti and Drohat 2011; Hashimoto, Hong et al. 2012), or deaminases that can
convert 5hmC into 5-hyroxymethyluracil (5hmU) in combination with base
excision repair (BER) mechanisms (Zhu 2009; Branco, Ficz et al. 2012; Hackett,
Zylicz et al. 2012; Morera, Grin et al. 2012). These hypotheses have drawn
special attention after the discoveries that the demethylation of paternal genome
follows a wave of hydroxymethylation (Iqbal, Jin et al. 2011; Wossidlo, Nakamura
et al. 2011); and that 5hmC can be further oxidized to 5-formylcytosine (5fC) and
then to 5-carboxycytosine (5caC) in vitro (Ito, Shen et al. 2011). However, 5fC
and 5caC was not detected during zygote development (Inoue, Shen et al. 2011).
Despite the recent accumulation of data, it is still not fully understood whether an
active demethylation event, that involves oxidization of 5hmC into 5fC and 5caC
followed by TDG-mediated base excision, takes place in vivo. (Cortellino, Xu et
al. 2011; He, Li et al. 2011; Maiti and Drohat 2011; Hashimoto, Hong et al. 2012;
Morera, Grin et al. 2012).
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Finally, the accumulation of 5hmC in the brain and the differential distribution of
5hmC on different loci between brain areas strongly support a stable epigenetic
role for 5hmC (Globisch, Münzel et al. 2010; Nestor, Ottaviano et al. 2011; Song,
Szulwach et al. 2011; Szulwach, Li et al. 2011). In this scenario 5hmC can (1)
evict proteins that bind methylated sequences; (2) recruit novel factors that avidly
bind hydroxymethylated sequences; and/or (3) change DNA structure within
chromatin.

I.XII. Intermission: a retrospective methodological evaluation
!

The addition of a third dimension to the cytosine modification status

necessitated the re-evaluation of the traditional methods to analyze genomic
methylation, since they operate in binary mode, where 5hmC, 5fC and 5caC
have been detected in either C or 5mC population.
•

Quantification methods

The traditional method to quantify global levels of methylation is nearest-neighbor
analysis (Ramsahoye and Mills 2002), where a restriction enzyme creates a
“sticky end” on DNA where it is labeled. The labeled nucleotides on these ends
are separated by chromatography. A second method is use of methylationsensitive restriction enzymes that can cleave DNA only if the target site is
unmodifed (Pells, Moore et al. 2006). However both methods limit the analysis to
a 4-6 bp site covering small part of the genome; they are biased for the
dinucleotide context, the resistance of 5hmC, 5fC and 5caC is unknown and the
former is also strongly dependent on the chromatography conditions
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(Ramsahoye and Mills 2002; Ito, Shen et al. 2011). Today, the most sensitive and
robust techniques to quantify modified nucleosides are high-performance liquid
chromatography, mass spectrometry and nanopore amperometry (Pomerantz,
McCloskey et al. 1990; Quinlivan and Gregory 2008; Clarke, Wu et al. 2009).
• Mapping methods

To analyze methylation status of specific loci scientists originally used MBDs to
enrich methylated DNA (Cross, Chariton et al. 1994; Rauch and Pfeifer 2005;
Rauch, Li et al. 2006). However each MBD exhibits a different binding pattern,
making this method inherently biased. For instance, in one study the genomic
localization of MeCP2 was shown to track with DNA methylation pattern (Skene,
Illingworth et al. 2010), which was evaluated using the MBD of the same protein
(Illingworth, Kerr et al. 2008). Furthermore, initially only a few selected loci were
analyzed (Meissner, Mikkelsen et al. 2008; Irizarry, Ladd-Acosta et al. 2009) until
genome-wide sequencing methods were developed. Currently methylated DNA
immunoprecipitation (MeDIP-Seq) is widely used in combination with highthroughput sequencing (Weber, Davies et al. 2005), while antibodies developed
for hydroxymethylated DNA immunoprecipitation (hMeDIP-Seq) show high
background, especially with repetitive sequences. (Jin, Kadam et al. 2010; Ficz,
Branco et al. 2011; Williams, Christensen et al. 2011; Xu, Wu et al. 2011).
Therefore, antibodies were developed against cytosine-5-methylenesulphonate,
product of bisulfite treatment of 5hmC (Ko, Huang et al. 2010; Pastor, Pape et al.
2011).
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In a recent chemical labeling technique, T4 bacteriophage β-glucosyltransferase
(βGT) transfers an azide-containing glucose moiety onto the hydroxyl group of
5hmC. The azide group then chemically incorporates a biotin group that can be
used for detection, affinity enrichment or sequencing (Song, Szulwach et al.
2011; Robertson, Dahl et al. 2012). Glucosylation reaction alone can also be
used for modification-resistant restriction enzymes that are blocked by
glucosylation. Finally, a restriction enzyme that has been cloned almost two
decades ago, cleaves DNA at hydroxymethylcytosine independent of sequence,
and its activity is also blocked by glucosylation (Janosi, Yonemitsu et al. 1994).
•

Base-resolution sequencing methods

In BS-Seq, DNA is treated with bisulfite, which converts all unmodified Cs into
uracils, and the comparison of the treated sequence to the original sequence
reveals 5mCs (Frommer, McDonald et al. 1992). Soon after the finding that
5hmC behaves like 5mC in BS-Seq whereas 5fC and 5caC behave like
unmodified C; new techniques were invented to incorporate 5hmC into BS-Seq
via an Tet-mediated or chemical oxidation step (Huang, Pastor et al. 2010; Booth,
Branco et al. 2012; Yu, Hon et al. 2012). In a single-molecule real-time
sequencing, kinetic signatures of a mutated DNA polymerase are monitored
during incorporation of fluorescent nucleotides (Flusberg, Webster et al. 2010).
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I.XIII. Tets: enzymes in the making of 5hmC
!

The methyl group of 5mC can be oxidized to 5hmC in vitro and in cell

cultures by any of the three recently identified members of the Ten-eleven
translocation (Tet) family of proteins, which belong to the superfamily of 2oxoglutarate- and iron-dependent dioxygenases (Fig 1.4) (Iyer, Tahiliani et al.
2009; Tahiliani, Koh et al. 2009; Ito, D'Alessio et al. 2010). TET1 and TET2 are
both implicated in cancer (Ono, Taki et al. 2002; Lorsbach, Moore et al. 2003;
Burmeister, Meyer et al. 2009; Abdel-Wahab, Mullally et al. 2009; Ko, Huang et
al. 2010); and so are enzymes that cause inhibition of Tets (Xu, Yang et al. 2011).
They are also the key enzymes responsible for the presence of 5hmC in ES
cells, as opposed to Tet3, which is highly expressed in terminally differentiated
tissues (Ito, D'Alessio et al. 2010; Koh, Yabuuchi et al. 2011). Although these
data suggest a role for Tet1 and Tet 2 in ES cell pluripotency and oncogenic
transformation; their roles in ES cell self-renewal and maintenance of pluripotent
state has been contradictory (Ito, D'Alessio et al. 2010; Dawlaty, Ganz et al.
2011; Koh, Yabuuchi et al. 2011; Williams, Christensen et al. 2011; Freudenberg,
Ghosh et al. 2012).
All Tet enzymes can oxidize 5hmC further into 5fC and 5caC in vitro (Inoue,
Shen et al. 2011). Evidence suggests that Tet3 mediates the demethylation of
paternal genome (Iqbal, Jin et al. 2011; Wossidlo, Nakamura et al. 2011),
whereas a recent report proposes a regulatory role for Tet1 in the expression of a
subset of meiotic genes during generation of oocytes (Yamaguchi, Hong et al.
2012). The increased methylation at many CGIs caused by depletion of Tet1 (Xu,
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Wu et al. 2011) and hypomethylation in patients with TET2 mutations (Ko, Huang
et al. 2010) also support a role for Tets in demethylation pathways, yet more
research needs to be done to establish a coherent model. Although active
demethylation has also been advocated in the brain, this hypothesis was based
on cultured neurons that over-expressed Tet1 (Guo, Su et al. 2011). In addition,
intermediate products, 5fC, 5caC and 5hmU were not detected in terminally
differentiated tissues (Globisch, Münzel et al. 2010; Pfaffeneder, Hackner et al.
2011).
In ES cells Tet1 also colocalizes with both active (Pastor, Pape et al. 2011) and
repressive histone marks, and also bivalent sites, that carry with both repressive
and activating marks (Wu, D'Alessio et al. 2011; Xu, Wu et al. 2011), with a
strong preference for unmodified CGIs within promoter regions and less within
gene bodies (Williams, Christensen et al. 2011; Wu, D'Alessio et al. 2011). This
suggests that it may also be functioning as a transcriptional modulator via its
CXXC domain (Zhang, Zhang et al. 2010), which is indeed dispensable for its
catalytic activity in vivo (Frauer, Rottach et al. 2011).

I.IV. 5hmC in the brain
!

The existing data can partly describe active demethylation events during

development, yet they are still not sufficient to explain the accumulation of 5hmC
in terminally differentiated cells. Although an active demethylation is advocated in
the brain, this hypothesis was based on cultured neurons that overexpressed
Tet1 (Guo, Su et al. 2011). In addition, intermediate products, 5fC, 5caC and
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5hmU were not detected in terminally differentiated tissues (Globisch, Münzel et
al. 2010; Pfaffeneder, Hackner et al. 2011). On the other hand, the location of
5hmC in the genome is significantly different in the brain, and most differentially
hydroxymethylated regions (DhMRs) between different neuroanatomical regions
are stable throughout life (Szulwach, Li et al. 2011; Chen, Dzitoyeva et al. 2012;
Wang, Pan et al. 2012). To gain more insight, our group recently mapped 5mC
and 5hmC in specific cell types in the brain, taking advantage of bacTRAP mice
(Heintz 2000; Heiman, Schaefer et al. 2008), that express a ribosomal protein,
L10A, tagged with enhanced green fluorescent protein (eGFP) in cell bodies (Fig
1.5.A) and nucleoli (Fig 1.5.B) of specific neuronal subpopulations. Having
eGFP-tagged ribosomes allowed both the enrichment of mRNA and the isolation
of genomes from specific cell types (Mellen, Ayata et al. 2012). In general, the
distribution of 5hmC across the genome in specific types of neurons and glia was
in agreement with previous studies of brain tissue (Song, Szulwach et al. 2011;
Szulwach, Li et al. 2011): 5hmC was preferentially enriched over the entire
transcription unit of expressed genes, and depleted from both the TSS and
intergenic regions. In highly expressed genes 5mC was depleted over the gene
bodies, whereas the enrichment of 5hmC varied between cell types. The patterns
of 5hmC and 5mC were inversely correlated. These findings by our group, a
recent study where 5hmC was found enriched in gene bodies of synaptic genes
(Khare, Pai et al. 2012), and the detection of DhMRs, support that 5hmC is a
stable epigenetic mark in the brain that is utilized in a clearly different manner for
neural functions.
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I.V. Epilogue: the search for 5hmC-binding proteins
!

5hmC revealing itself as a stable and activating mark in the brain, raises

immediate questions: (1) by which upstream events is this epigenetic code
written at specific locations in the brain that differ from pluripotent cell states; and
(2) by which downstream implications is it interpreted as a stable and activating
mark. The aim of this study is to address the second question by trying to unveil
nuclear factors that recognize the 5hmC mark in the brain. Factors that bind to
methylated DNA, have elucidated the main mechanisms that convert 5mC into a
repressive mark. Two 5hmC-binding proteins have been previously reported:
First, Frauer et al. showed that Uhrf1 recognizes hydroxymethylated CpGs
(5hmCpGs) (Frauer, Hoffmann et al. 2011). Although this finding was informative
for the maintenance of 5hmC, it did not provide any insight of its interpretation as
an epigenetic mark. Later, Yildirim et al. demonstrated that Tet1 and MBD3
colocalize in ES cells (Yildirim, Li et al. 2011). This study proposed an alternative
control of gene expression of bivalent genes in pluripotent cells, by the repressor
MBD3 and activator Brg1. Yet this group also could not establish a direct
functional link between 5hmC and active chromatin states in postmitotic cells.
The study we present here, attempts to solve this conundrum by identification
and functional characterization of brain-specific proteins that recognize 5hmC.
Thus, we hope to elucidate mechanisms that can read the 5hmC code and
translate it into an activation mark in the brain.
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Chapter II.
MeCP2 binds to 5hmC at CpA dinucleotides enriched
in the bodies of the active genes in euchromatin
II.I. MeCP2 is an abundant 5hmC binding protein
!

To identify the factors that may be responsible for decoding 5hmC in the

brain, nuclear extracts prepared from rodent brain (Klose and Bird 2004) were
incubated with magnetic beads coated with DNA containing unmodified C, 5mC
or 5hmC in the presence of excess non-specific DNA competitor. After the beads
were isolated, proteins captured on the beads were eluted and separated on
SDS PAGE. Silver staining of this gel revealed a band of ~70 kDa enriched with
both 5mC and 5hmC, but not with C (Fig 2.1.A). This band was excised from a
preparative gel of this type, analyzed by mass spectroscopy and identified as
MeCP2 in a peptide database search with ~50% sequence coverage (Fig 2.1.B).
Since it is possible that novel low-abundance 5hmC binding proteins might be
obscured by the abundant MeCP2, we repeated this experiment in the absence
of MeCP2. Nuclear extracts were prepared from Mecp2-KO animals using beads
coated with DNA containing C or 5hmC. Upon visualization by Coomassie or
more sensitive Silver stain, we did not detect any 5hmC-specific bands in the
eluates from KO animals (data not shown). As an alternative detection, we
transferred the electrophoresed eluates from wild type (WT) and KO onto a
charged membrane and analyzed it by Southwestern blotting method
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(Campoy, Meehan et al. 1995). Thus, membrane bound re-natured proteins were
probed with DNA end-labeled with

32P

isotope containing either 5mC or 5hmC,

revealing a protein of the correct molecular weight that can bind both 5mC and
5hmC containing DNA probes from WT animals, and that is not present in
samples prepared from KO animals (Fig 2.1.C). To our surprise, no other
abundant protein with high specificity for 5hmC DNA was revealed in these
studies, even in the absence of MeCP2.

II.II. Recombinant MeCP2 specifically binds to 5mC and 5hmC
!

To test the binding of MeCP2 to 5hmC directly, a His-tagged N-terminal

fragment (NT) of human MeCP2 containing the MBD (residues 1-205) was
produced in E. coli and purified using Nickel-nitrilotriacetic acid (Ni-NTA) resin
(Fig 2.2.A). Probes with C, 5mC or 5hmC nucleotides were prepared (Fig 2.2.B)
and used in electrophoretic mobility shift assays (EMSA) to measure binding. At
all concentrations tested, the MeCP2 NT failed to bind the C-containing probe,
while avidly binding both the 5mC and 5hmC probes (Fig 2.2.C).We also have
purified the minimal MBD (residues 77-167) of MeCP2 and confirmed that MBD
was sufficient for this binding (Fig 2.2.D). As an additional control, EMSAs also
were performed using probes reacted with T-4 phage β-glucosyltransferase
(βGT), which adds a glucose from uridine diphosphoglucose (UDP-glucose)
specifically to the -OH group of 5hmC without affecting 5mC and C nucleotides
(Szwagierczak, Bultmann et al. 2010). The binding of MeCP2 NT to the
glucosylated 5hmC probe was blocked due to glucosylation of 5hmC residues
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and retained as 5mC, which is refractive to glucosylation (Fig 2.2.E). MeCP2
binding to 5hmC was not sequence specific since the binding properties of
MeCP2 to a variety of probes selected from the mouse genome did not vary
significantly.
We set up to examine the modification-specific interaction of other MBD family
proteins. A schematic view of the recombinant fragments of MBDs is shown in
Fig 2.3.A. We purified His-tagged MBDs 1 through 4 using a column prepared
with Ni-NTA (Fig 2.3.B) (Janknecht, de Martynoff et al. 1991). In contrast MBD1,
2 and 4 all bound strongly to 5mC containing DNA, and did show specificity to
5hmC containing probes (Fig 2.3.C). As previously reported (Yildirim, Li et al.
2011), binding of MBD3 was observed to both 5mC and 5hmC DNAs, and the
mobility of the MBD3/5hmC complex was slightly retarded relative to the
MBD3/5mC complex. MBD3 binding to both 5mC and 5hmC was much weaker,
requiring amounts that are two orders of magnitude higher than the other MBD
proteins, and its binding to 5hmC DNA was sensitive to glucosylation. A weak,
5hmC-specific and βGT-sensitive was also observed with MBD4.
We verified these observations by competition assays: in the absence of a
nonspecific competitor, unlabeled, or “cold” probes containing 5mC and 5hmC
can compete out the binding of MeCP2 to radioactively labeled, or “hot”, 5mCcontaining DNA probe with the same efficiency (Fig 2.4.A). This effect is much
less pronounced for C. On the contrary, “cold” 5mC-containing probe could
compete out the binding of MBD1 and 2 to radioactive probe containing 5mC,
much more efficiently than “cold” probes containing C or 5hmC (Fig 2.4.B and C).
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II.III. RTT mutation R133C preferentially inhibits binding to 5hmC
!

If binding of MeCP2 to 5hmC is critical for its role in the regulation of

neuronal nuclear function and gene expression, then it is possible that a subset
of the MeCP2 mutations that cause RTT disrupt 5hmC binding without strongly
impacting 5mC interaction. To determine if this is the case, binding of MeCP2
MBDs (aa 1-205) carrying a variety of previously characterized RTT mutations
were assayed (Kudo, Nomura et al. 2003). Here we focused on residues that (1)
do not alter the MeCP2 binding and nuclear localization significantly, (2) located
in the DNA binding pocket, and (3) show atypical or mild phenotypes in RTT
database (http://mecp2.chw.edu.au/mecp2/). We also included a newly identified
mutation S134F (Lima, Brunoni et al. 2009). To represent two extreme cases of
DNA binding activity three mutations were selected: D121G, that abolishes 5mC
binding, and L100V and A140V, that donʼt directly interact with DNA, maintain
wild type affinity to 5mC and show milder phenotypes (Orrico, Lam et al. 2000;
Couvert, Bienvenu et al. 2001; Jentarra, Olfers et al. 2010). The rest of the
disease-causing mutations in the MBD were chosen because they showed no or
little disruption of nuclear localization or 5mC-binding. We produced these in E.
coli and purified as previously described (Fig 2.5.A). Although the general effect
of mutations in this series was to inhibit binding to both 5mC and 5hmC DNAs to
a similar degree or to remain unchanged, we observed a pronounced decrease
in the interaction with 5hmC relative to 5mC DNA with the MeCP2 MBD carrying
the R133C substitution (Fig 2.5.B).
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Since R133C and R133H are mutations at the same location, yet give different
affinities for modified probes, next we wondered if it would be possible to
“improve” this differential binding by designing artificial mutants that bound 5mC
as efficiently as WT and showed nonspecific binding to both 5hmC and C. Hence
we designed R133 mutants by replacing the positively charged R residue with
another positively charged residue of smaller size (R133K), a negatively charged
residue (R133E), a hydrophobic residue (R133M) and a hydrophilic residue
(R133S). The binding of most of these mutants to 5mC was not affected yet their
binding to 5hmC was reduced (Fig 2.6.A). This discrepancy was pronounced with
residues that contain a negatively charged atom such as sulfur (in R133C and
R133M) and oxygen (in R133E and R133S). We hypothesize that this is due to
their vicinity to the oxygen of the hydroxyl group of 5hmC. The binding of mutants
containing R133H and R133K to both 5mC and 5hmC was strongly reduced (Fig
2.6.B). To test whether this effect is also conserved in the full-length (FL)
proteins, we purified FL WT MeCP2, the RTT mutation R133C and two of the
artificial mutants R133E and R133S. Since the FL protein cannot be separated in
EMSA gel, we separated these proteins on SDS page (Fig 2.6.C), transferred
them onto a charged membrane, and analyzed it by Southwestern method as
before. The membrane-bound re-natured proteins were probed with radioactive
DNA probes containing either 5mC or 5hmC (Fig 2.6.D). We normalized the
signal of both membranes to the signal from WT NT of MeCP2 and detected no
binding activity of R133C and R133E mutants to 5hmC containing DNA, whereas
R133S showed weak binding to 5hmC.

44

45

II.IV. Binding of MBD proteins to C, 5mC and 5hmC
!

To investigate these findings in more detail, and to provide independent

data supporting the conclusions of the EMSA assays presented above, surface
plasmon resonance (SPR) assays were used to measure the binding of full
length MeCP2, the MeCP2 MBD, other MBD proteins, and the MeCP2 carrying
R133C mutation to 5hmC, 5mC and C containing DNA (Malmqvist 1999). 5ʼbiotinylated DNA probes prepared using C, 5mC or 5hmC nucleotides were
immobilized on parallel flow cells (Fc) of a streptavidin-coated sensor chip to a
level of 500 (±25) resonance units (RU). Several dilutions of purified recombinant
proteins were then introduced to each Fc in parallel and the change in SPR
response over time was recorded. By visual inspection of overlay plots of such
response by MeCP2 NT and MBD2, the specific binding of MeCP2 to both 5mC
and 5hmC and the specific binding of MBD2 to 5mC were readily observed (Fig.
2.7.A). Next, we plotted the SPR response of these proteins at saturation against
the corresponding protein concentration, to represent the steady-state binding
(Fig 2.7.B). As predicted, MeCP2 NT showed specific binding to both 5mC and
5hmC containing DNA that was strongly dependent on protein concentration,
whereas binding to C-containing DNA plateaued at very low protein
concentrations, consistent with nonspecific binding. In contrast, MBD2 bound
strongly to 5mC-containing DNA and did not bind to DNA containing C or 5hmC.
We then expanded these assays to other MBDs, FL MeCP2 and FL MeCP2
containing the R133C point mutation. In SPR experiments MBD3 did not show
specific binding to any probe (data not shown). As expected, MBD1 and 4
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showed specific binding only to 5mC DNA (Fig 2.8.A). As predicted, the binding
characteristics of FL MeCP2 was as NT (Fig 2.8.A), consistent with the pull down
experiments, the Southwestern results and the EMSA data presented above.
Interestingly, binding of the MeCP2 R133C mutant to 5hmC was very strongly
depressed relative to binding to 5mC DNA, although a small effect on overall
binding to 5mC was evident. To further assess these results, the Bmax of
proteins binding to each probe were calculated from steady-state binding curves
to generate quantitative binding data for each protein (Fig 2.8.B). No significant
difference was observed in the measured Bmax of MeCP2 binding to 5mC and
5hmC. The most interesting and unexpected outcome of these calculations is
that the R133C MeCP2 mutant retained most of its 5mC binding capability (Bmax
= 76% of WT, p=0.77) despite loss of specific binding to 5hmC (Bmax = 25% of
WT, p = 0.0029). The fact that this single substitution in the MeCP2 MBD can
strongly and preferentially impact the substrate binding properties of MeCP2 is
important because identification of MeCP2 mutations that retain WT 5mC
binding, in the R133C variant yet retain severely diminished 5hmC binding can
provide an important avenue for assessing the role of MeCP2 binding to 5hmC in
the pathophysiology of RTT. Furthermore, these data demonstrate that small
changes in the structure of MeCP2 may influence its relative binding properties to
5mC and 5hmC, raising the interesting possibility that the posttranslational
modifications to MeCP2 that have been shown to occur in response to a variety
of stimuli (Chen, Chang et al. 2003; Tao, Hu et al. 2009; Rutlin and Nelson 2011)
could alter its substrate specificity and downstream functions.
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II.V. MeCP2 binds to 5hmC and 5mC in CpA context
!

The identification of MeCP2 as a major 5hmC binding protein in rodent

brain is surprising given previous in vitro studies reporting that it binds 5mCcontaining DNA much more avidly than 5hmC-containing DNA (Valinluck, Tsai et
al. 2004; Bostick, Kim et al. 2007). The most notable difference between previous
studies and ours was the preparation of the DNA: Other studies utilized probes
prepared by dimerization of chemically synthesized short oligonucleotides with a
single modification in CpG context, where we amplified probes from a native
genomic sequence using dCTP, d5mTP or d5hmTP. The resulting probe is a 120
bp probe that is densely modified (as in some regions of the genome) where the
modified residues can exist in every possible dinucleotide context. To address
this issue directly, we prepared probes that were modified on a single C in all
dinucleotide and trinucleotide contexts. In order not to compromise the DNA
binding of MeCP2 we used long, 75 bp, probes rich in A/T bases near the
modification. To our surprise, MeCP2 failed to bind to the 5hmCpG dinucleotide,
in agreement with the earlier studies, yet its binding was nearly as strong for the
5mCAC trinucleotide as well as 5hmCAC (Fig 2.9.A). It bound with similar affinity
to both 5mCAT and 5hmCAT trinucleotides. We observed considerably low
binding with 5mCGA and 5mCAA trinucleotides, but binding was abolished in
5hmCGA and 5hmCAA. MeCP2 also did not bind any CpC or CpT nucleotides or
any of the hybrid CpGs, where the modification status of the two strands differed
(data not shown). In addition, R133C mutant conserved the binding to 5mCpG
and 5mCpA but lost its affinity to hydroxymethylated CpAs (5hmCpAs), indicating
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that R133 residue is crucial for 5hmC recognition but not for the recognition of
the subsequent pyrimidine (Fig 2.9.B). As expected, both MBD1 and MBD2 did
not bind either DNA containing C or 5hmC, or 5mC in CpA context. MBD2 bound
DNA with a single 5mCpG strongly; however, MBD1 showed low binding. The
identity of the fourth nucleotide did not affect binding (data not shown).
We next performed pulldowns in nuclear extract from rodent brain using DNA
baits carrying a single modification in CpA or CpG context, enriched MeCP2 in
DNA-bound eluates by immunoprecipitation and confirmed our binding data by
Western blot of the euates using an antibody against MeCP2 (Fig 2.9.D, left).
Interestingly, when we used an anti-phosphoserine antibody, we saw a band
specific for proteins eluted from the methylated DNA bait (Fig 2.9.D, right).
However, we cannot currently conclude that the source of this band is MeCP2.
To analyze this binding more in detail, we conducted a new generation SPR
analysis (Abdiche, Lindquist et al. 2011), where we immobilized biotinylated DNA
probes containing a single CGCT, 5mCGCT, 5hmCGCT, 5mCACT and
5hmCACT on a neutravidin-coated array to a level of 550 (±40) RU and
measured the response by several dilutions of WT MeCP2 NT and R133C in
parallel. The equilibrium analysis was performed using ProteOn Software. As
expected, MeCP2 showed specific binding to 5mCpG, 5mCpA and 5hmCpA (Fig
2.10.A). Interestingly, the binding of R133C mutant to 5mCpG was at WT levels,
yet its binding to 5mCpA was reduced. We observed more significant effect on its
5hmCpA binding. To verify our observations, we extracted Bmax values using
ProteOn Software for each protein and DNA modification (Fig 2.10.B).
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These results showed that MeCP2 preferentially binds a methylated site within
the context Cp(A/G)p(T/C) > Cp(A/G)p(A/G), whereas hydroxymethylated target
sites are within the context CpAp(T/C). Since non-CpG modification, primarily
CpA(C), makes up 20-25% of the modified cytosines (Laurent, Wong et al. 2010),
it is likely that a substantial population of MeCP2 is bound on modified CpAs in
vivo. Additionally, modified non-CpG sites are are preceded by a TA dinucleotide
upstream and followed by an A or T (Lister, Pelizzola et al. 2009). Such pattern
may be stabilizing the binding by MeCP2 which possesses two consensus A/Thook motifs of MeCP2 (Ho, McNae et al. 2008). Given that modified CpAs are
concentrated in the bodies of active genes and strongly correlate with gene
expression (Lister, Pelizzola et al. 2009), and that genes that are highly
expressed lack methylation but are largely hydroxymethylated (Mellen, Ayata et
al. 2012), one can expect that such genes have high levels of hydroxymethylated
CpAs. Although single nucleotide data is not yet available, asymmetrical
hydroxymethylation is observed at high levels throughout the transcription unit of
active genes, and such regions contain extensive amounts of modified non-CpG
dinucleotides (Ficz, Branco et al. 2011). If a considerable fraction of MeCP2
target sites are hydroxymethylated CpAs enriched in the bodies of active genes
within euchromatin, we hypothesize that these sites may be bound in vivo by the
previously identified subpopulation of MeCP2, that is loosely bound and
associated with active states of genes and chromatin (Thambirajah, Ng et al.
2011).
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II.VI. MeCP2 facilitates chromatin accessibility around 5hmC
!

Given that MeCP2 can not only tightly bind densely packed regions of

silent chromatin, enriched in 5mC, but also is loosely associated with accessible
regions of chromatin, which are where active genes, 5hmC and modified CpAs
are extensively found, we next were interested in assessing its potential role in
global regulation of chromatin accessibility. To do so, cerebellar nuclei were
isolated from five-week-old WT and KO male mice (Guy, Hendrich et al. 2001).
For each sample, a time course of MNase digestion was performed, and the
release of 5hmC- and 5mC-enriched DNA fragments prepared by Southern
blotting and assayed with antibodies against 5mC and 5hmC (Fig 2.11.A). To
quantitate and normalize the data from different digestions, the signal from
quadrant 1 (Q1) to Q4 in each lane was measured in four independent cohorts of
WT and KO mice, and the data quantified as the percentage of total signal in
each time of digestion (Fig 2.11.B). We denoted the signal present in the Q1
fraction as nuclease-resistant fraction and plotted that against the early digestion
times (Fig 2.11.C). Two interesting results were obtained: First, we observed that
5hmC-enriched DNA is released readily from chromatin by MNase digestion,
whereas 5mC-containing chromatin is significantly more resistant to digestion.
This is consistent with the analysis of individual genes, and confirms previous
studies demonstrating the 5mC enriched DNA is present in MNase-resistant
compact structures (Karymov, Tomschik et al. 2001). Second, in Mecp2-null mice
a significant, small delay in digestion of 5hmC-containing DNA was observed,
whereas no reproducible difference in the sensitivity of 5mC-containing DNA to
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MNase was evident. These data demonstrate that MeCP2 regulates the
accessibility of 5hmC-containing DNA to MNase, supporting a model in which
MeCP2 binding to 5hmC within highly expressed genes may facilitate
transcription through its effects on chromatin organization.

II.VII. Discussion
!

The data presented here identify a novel role for MeCP2 in the regulation

of chromatin structure in support of a new model for the organization of
accessible chromatin states around expressed genes that is specific to the
vertebrate nervous system, in addition to the traditional repressive and silencing
functions it elicits upon its binding to 5mCpG dinucleotides (Guy, Hendrich et al.
2001). Based on the previous literature and our findings, we propose that binding
of 5hmCpA by MeCP2 plays a central role in the fine tuning of chromatin states
that facilitate expression of neural genes. The mechanism by which MeCP2
binding to 5hmCpA regulates chromatin accessibility is evidently different from its
repressive role within heterochromatin regions enriched in 5mC and remains to
be deciphered. However this model, based on our binding data, is substantiated
by the fact that both 5hmC and MeCP2 are at least an order of magnitude more
abundant in the nervous system than in the periphery (Kriaucionis and Heintz
2009; Skene, Illingworth et al. 2010); that both modified CpA dinucleotides and
5hmC are abundant on bodies of active neural genes and euchromatin; that
these regions are depleted of 5mC (Lister, Pelizzola et al. 2009; Mellen, Ayata et

57

al. 2012); and that MeCP2 has a yet uncharacterized association with accessible
chromatin states (Thambirajah, Ng et al. 2011).
• 5hmCpA, a new epigenetic code in the brain

The accumulation of modified CpA throughout the transcription unit of active
genes (Lister, Pelizzola et al. 2009; Ficz, Branco et al. 2011), combined with the
signature depletion of 5mC and accumulation of 5hmC throughout bodies of
highly expressed genes (Mellen, Ayata et al. 2012), imply a new depiction of
epigenetic information in the form of 5hmCpA in correlation with gene expression.
This differs significantly from the traditional epigenetic language, where 5mCpGs
compact chromatin into repressive states via MBD and other 5mC-binding
proteins (Guy, Hendrich et al. 2001; Yildirim, Li et al. 2011). Since CpA
modification is inherently “asymmetric”, it is destined to be lost over cell divisions.
Hence in post-mitotic cells, de novo mechanisms are necessary to establish such
code that potentially define cell identity and function. This is crucial for a complex
network, like the brain, where each cell fulfills a slightly or fundamentally different
function from its sister cell. Indeed, non-CpG modification of transcription units of
highly expressed neuronal genes has been previously reported (Backdahl,
Herberth et al. 2009; Cortese, Lewin et al. 2011). It is likely that neuronal genes
can be methylated at CpA dinucleotides by Dnmt3a in an activity-dependent
manner; given its neuron-specific euchromatic localization (Wu, Coskun et al.
2010); its ability to methylate CpAs in vivo (Mund, Musch et al. 2004); and its
activity-dependent regulation in neurons (Feng, Chang et al. 2005; Miller and
Sweatt 2007; Nguyen, Meletis et al. 2007; LaPlant, Vialou et al. 2010). Moreover,
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the de novo DNA methyltransferase, Dnmt3b, is not detected in postmitotic tissue
(Okano, Bell et al. 1999). Although not much is known about Tet3, we suspect
that its functions may encompass the hydroxylation of 5mCpAs, since all Tet
enzymes can hydroxylate methylated CpAs in vitro (Tahiliani, M, personal
communication); Tet3 is highly expressed in the brain (Szwagierczak, Bultmann
et al. 2010); and in the absence of Tet1 and Tet2, asymmetric non-CpG
hydroxymethylation increases (Ficz, Branco et al. 2011). Together these data
suggest that Dnmt3 and Tet3, or other putative enzymes, may be generating high
amounts of 5hmCpA. In the brain, both 5hmC and modified CpAs share a similar
pattern: both are depleted in TSS, but enriched the bodies of highly expressed
genes within euchromatin (Lister, Pelizzola et al. 2009; Mellen, Ayata et al. 2012),
therefore we expect that a large proportion of these modified CpAs to be
hydroxymethylated. This is strongly supported by the finding that these genes are
invariably depleted from 5mC.
• MeCP2, the reader of the new language

In this study, we have shown that MeCP2 binds 5hmCpA in vitro. To appreciate
this binding at the molecular level, we have modified the existing structural
information (Wakefield, Smith et al. 1999) using Pymol software. The original
structure (Fig 2.12.A) conveys the hydrophobic stabilization of the methyl group
of 5mC by the arginine chain, as well as the ionic interaction between the
negative oxygen of guanine (G) and the amino group of arginine (R). When the
methyl group is oxidized in 5hmC (Fig 2.12.B), then two highly negative oxygen
molecules in 5hmC and G make the interaction unfavorable, whereas the
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replacement of G by adenine (A) restores the ionic balance. The molecular
representation of a cysteine residue replacing the arginine (R133C) also provides
mechanistic insight to the preferential inhibition of 5hmC binding of MeCP2. In a
hypothetical model, where R133C MeCP2 is bound to 5hmCpA (Fig 2.12.D), the
nucleophilic sulfur of cysteine would be adjacent to the oxygen of 5hmC. That
would create an energetically unfavorable state and thus binding would not
occur. On the other hand, in the 5mCpG-bound R133C MeCP2, the oxygen of G
and the sulfur atom of cysteine are separated where water molecules may be
accommodated and stabilize 5mCpG in the binding pocket (Fig 2.12.C). Same
effect can be observed in some of the other R133 mutants we have created,
where the distance between the oxygen of 5hmC and an other nucleophilic atom,
such as sulfur in R133M (Fig 2.13.B) or oxygen in R133E or R133S (Fig 2.13.D
and E), is too small to be energetically favored. In the case of R133K and
R133H, such strong repulsion is not the case and accordingly, the discrepancy
between 5mC and 5hmC binding is smaller. However, the 5mC binding is more
strongly reduced. This may be due to steric hinderance and/or displacement of
water molecules that stabilize the binding pocket (Ho, McNae et al. 2008).
Given our binding data; and that both 5hmC and MeCP2 are at least an order of
magnitude more abundant in the nervous system than in the periphery
(Kriaucionis and Heintz 2009; Skene, Illingworth et al. 2010); we hypothesize that
MeCP2 binding to 5hmCpA is crucial in the decryption of the new neuronal
epigenetic code, which we proposed earlier. This code is not accessible to other
MBD proteins, as they neither recognize 5hmC nor modified CpAs. On the other
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hand, 5hmCpA is likely to be occupied by MeCP2 in vivo, not only because
MeCP2 avidly binds 5hmCpA in vitro, but also because MeCP2 contains two
consensus A/T-hook motifs (Ho, McNae et al. 2008), that may be stabilized by
the TA dinucleotide upstream of modified non-CpG and the A/T downstream
(Lister, Pelizzola et al. 2009). This suggests that the interaction interphase of
MeCP2 with 5hmCpA may be different than stable complexes established around
5mCpG by binding of MeCP2 or other less abundant MBD family proteins
(Lopez-Serra, Ballestar et al. 2006), since the target site is proven to be an
activating mark within accessible chromatin.
In individual cell types, the level and genomic location of 5hmC and 5mC are
tightly regulated (Szulwach, Li et al. 2011; Mellen, Ayata et al. 2012) and the local
protein composition associated with them varies (Lopez-Serra, Ballestar et al.
2006; Clouaire and Stancheva, 2010). Then a delicate balance between 5mC,
5hmC, MeCP2 and other MBD proteins may explain the fine tuning chromatin
states that enable elaborate adjustments of gene expression patterns. As a
result, changes in the function of MeCP2 (Amir, Van den Veyver et al. 1999; Tao,
Hu et al. 2009; Adkins and Georgel 2011) will disrupt such balance at varying
severity in each cell type, and the phenotypic consequences will be cell-type and
circuit specific. In mice, after the neurodevelopment is completed in the
cerebellum and MeCP2 expression reaches a plateau (Skene, Illingworth et al.
2010), ~85% of DhMRs within specific tissues are stably maintained (Szulwach,
Li et al. 2011). Interestingly, these stable DhMRs are not altered in the absence
of Mecp2, supporting the downstream role of MeCP2 in these regions. Although
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the total 5hmC signal increased by <20% in the absence of Mecp2, this change
was restricted to gene body DhMRs, leading the scientists to propose a genebody specific role for MeCP2 (Szulwach, Li et al. 2011).
• Bilingual MeCP2

The exact mechanisms by which 5hmCpA is interpreted by MeCP2 into open
chromatin states to facilitate gene transcription is still unclear. Binding to
5hmCpA within euchromatin and active genes, in addition to 5mCpG within
heterochromatin and silent genes, juxtaposes two contradicting roles for MeCP2.
Intriguingly, a similar contradiction has been presented in the earlier studies: the
apparent action of MeCP2, that is more akin to a linker histone coating the whole
genome (Skene, Illingworth et al. 2010) and the detection of two populations of
MeCP2 in the brain, one loosely bound in highly accessible chromatin domains
and the other tightly bound in heterochromatin regions that are rich in
nucleosomes (Thambirajah, Ng et al. 2011). It is likely that this latter population of
MeCP2 can stably associate with nucleosomes participating in methylated
regions in heterochromatin (Chandler, Guschin et al. 1999). The euchromatic
MeCP2 population, however, may be occupying expressed genes through its
binding to 5hmCpA (Fig 2.14.A). Since the 50% of the demand for histone H1 is
supplied by MeCP2 in the brain (Skene, Illingworth et al. 2010; Ghosh, HorowitzScherer et al. 2010), the regulation of global chromatin state in neurons might as
well be largely mediated by the distribution of different populations of MeCP2
over the neuronal genome. We propose that a population of MeCP2 is loosely
bound to 5hmCpA within active transcription units and facilitates chromatin
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accessibility by unknown mechanisms, with other populations still being tightly
associated with silent chromatin. This model provides a possible explanation for
the recent demonstration that Mecp2 gene dosage positively correlates with the
expression of the majority of the genes in the brain (Chahrour, Jung et al. 2008;
Ben-Shachar, Chahrour et al. 2009). If the distribution of MeCP2 over the whole
genome fine tunes accessible and silent chromatin states, then a dosedependency should be crucial. Indeed, changes in the level or activity of MeCP2
that disturbs this balance results in alterations of chromatin structure and,
consequently, gene expression. This has been manifested by the disease
phenotypes that arise when MeCP2 is overexpressed by only two-fold (Collins,
Levenson et al. 2004) and when the activity-dependent posttranslational
modifications of MeCP2 were impaired (Cohen, Gabel et al. 2011; Li, Zhong et al.
2011). An interesting strategy to observe the consequences of such balance
shifts would be to manipulate 5hmC levels in vivo and observe how MeCP
populations dislocate and how this is reflected in the phenotype.
• R133C, lost in translation

Our understanding of the pathophysiology of RTT must now encompass both the
role of MeCP2 binding to 5mC in the silent chromatin states (Chahrour, Jung et
al. 2008), and present results supporting a model in which MeCP2 binds to 5hmC
within active transcription units (Fig 2.14.A). Our finding suggests that diseasecausing mutation R133C displaces euchromatic MeCP2 and shifts the balance
towards heterochromatin-associated MeCP2 (Fig 2.14.B). Because of the
observations that the distribution of 5hmC, 5mC and their relationship to gene
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expression vary depending on the cell type, the change in the distribution of
MeCP2 population upon R133C mutation may present an important avenue
toward understanding the biochemical mechanisms causing qualitative and
quantitative aspects of RTT phenotype. It is well documented that patients
carrying the R133C mutation have a milder form of RTT that is characterized by
delayed-onset regression, with improved speech and motor skills (Bebbington,
Anderson et al. 2008). However, for many other characteristics, including
breathing abnormalities, sleep problems, mood disturbances, and epilepsy
prevalence, no significant differences are evident between patients bearing
R133C or other mutations (Bebbington, Anderson et al. 2008).
Although some studies presented data supporting that R133C mutation impairs
the binding of 5mC by MeCP2 (Ballestar, Yusufzai et al. 2000; Ballestar and
Wolffe 2001), our results and other studies contradicted this idea, showing that
this mutation shows binding characteristics that are closer to WT than other
mutations in the MBD (Kudo, Nomura et al. 2003; Ghosh, Horowitz-Scherer et al.
2008; Kumar, Kamboj et al. 2008; Mund, Musch, et al. 2004; Fan, Nikitina, et al.
2005). Although it is possible that a mild impairment in 5mC binding might be
important for the RTT phenotypes, another attractive scenario is that the
complete loss of 5hmC binding (Fig 2.12.D) is the primary cause of these latter
clinical features of RTT. In this scenario, the R133C mutant of MeCP2 retains its
5mC binding ability to maintain repression of silent genes, whereas the fine
tuning of accessible chromatin states via 5hmC-binding are disrupted.
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• Where is 5hmCpA?

Although this study identifies a new role for MeCP2 bound to 5hmCpA, there are
still many unanswered questions: First, we still donʼt know the mechanism of how
the CpA is hydroxymethylated in resting or activated states in the CNS. With the
recent advancement in the sequencing techniques, it is now possible to
sequence hydroxymethylomes genome-wide and in base-resolution (Flusberg,
Webster et al. 2010; Huang, Pastor et al. 2010; Booth, Branco et al. 2012; Yu,
Hon et al. 2012). Comparison of hydroxymethylomes and methylomes within cell
populations or individual cells, and between active and resting states, will
introduce the epigenetic information in the brain. It is now widely accepted that a
quarter of global methylation occurs within non-CpG context (Ramsahoye,
Biniszkiewicz et al. 2000; Lister, Pelizzola et al. 2009), yet an increased ratio of
non-CpA dinucleotides within active gene bodies is highly probable, since an
enrichment of 5mCpA is observed in such regions.
• What are multiple identities of MeCP2?

We donʼt know the identity of “populations” of MeCP2. Based on recent studies
we postulate that one or more posttranslational modifications might be a switch
for distribution of MeCP2 in such populations (Cohen, Gabel et al. 2011). It is
also probable that the binding of MeCP2 to 5hmCpA is mechanistically different
from its binding to 5mC (a hypothetical rearrangement of R133 residue of MeCP2
is shown in Fig 2.15.B-C), causing a structural change in MeCP2 and its readout
in downstream protein-protein interactions. On the other hand, due to the intrinsic
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disorder of MeCP2, even if this kind of structural change was taking place, it may
not have long range effects on the protein structure.
We do not have in vivo binding information of MeCP2. Since MeCP2 is a
dynamically bound protein that exists in different populations that occupy different
genomic regions at different times, a simple ChIP assay will bring down mixed
populations of MeCP2 and, thus, will not be informative. For this kind of analysis,
the identity of different MeCP2 populations is a prerequisite. Complimentary to
the identification of in vivo binding sites of MeCP2, comparison of changes in the
distribution of 5hmC within euchromatin and heterochromatin in the absence of
Mecp2 also would shed light into the contribution of MeCP2 species to the
arrangement of chromatin states. This could be achieved by immunostaining
5hmC and 5mC; and comparison of the layout of the chromatin around
hydroxymethylated regions in different cell types between the KO and WT mice.
In previous studies, smaller and more compact nuclei were observed in Mecp2
deficiency (Chen, Akbarian et al. 2001; Cheung, Horvath et al. 2011). We have
also observed a subtle decrease in the overall nuclease sensitivity of chromatin
that is more pronounced in 5hmC-rich regions.
We expect a great deal of insight into MeCP2 function to be revealed by in vivo
studies with mice carrying R133C mutation, where the balance between MeCP2
populations is disrupted. If 5hmC-bound MeCP2 is involved in the fine regulation
of the expression of certain neural genes, depending on the neuronal activity and
cell type, then it is possible that 5hmC plays a role in the phenotypes that result
in categorization of RTT as an Autism Spectrum Disorder.
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• What else is out there?

Currently we do not have single-base resolution hydroxymethylome of the brain
tissue. However we can expect that there still is a substantial amount of 5hmC
within CpG context, which is not recognized by MeCP2. Therefore, alternative
mechanisms may contribute to the decoding of 5hmC. We do not know whether
5hmC-mediated demethylation events play a role in the activity-dependent
changes in the neuronal epigenome (Guo, Su et al. 2011) or if demethylation
pathways are fundamentally different epigenetic mechanisms, carried out by a
different subset of Tet enzymes during development. This finds support in the
high level of DhMRs that are lost during neurodevelopment (Szulwach, Li et al.
2011). We also do not understand where MBD3 binding to 5hmC in ES cells
(Yildirim, Li et al. 2011) fits in this model. We cannot presently answer these
questions, yet in this study we have identified a novel MeCP2-mediated decoding
mechanism of the epigenetic cryptogram that is unique to the brain and found an
unexpected link to a critical new function for the RTT-causing protein MeCP2.
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Chapter III.
Identification of a novel 5hmC-specific complex
containing Purα
III.I. A novel 5-hmC-specific complex in brain nuclear extract
!

Although MeCP2 binding to 5hmC offers a new way of understanding the

regulation of chromatin in the nervous system, it is possible that there are other
novel 5hmC-binding proteins in the brain that were not detected in our studies
previously due to methodological limitations. To further investigate this possibility,
crude nuclear extract from rodent brain (Klose and Bird 2004) was directly
assayed in EMSAs with radioactively labeled DNA probes containing C, 5mC or
5hmC in the presence of an excess of non-specific DNA competitor at a range of
dilutions. To our surprise, a 5hmC-dependent low-mobility complex was apparent
at extract concentrations ~0.8 μg (Fig 3.1.A). This complex was much less
obvious with probes containing C or 5mC nucleotides. The quantification of the
signal at the observed mobility revealed 4- to 10-fold enhancement of 5hmCdependent signal at the observed location compared to the other probes (Fig
3.1.B). The appearance of this complex was not tightly dependent on the amount
of nonspecific competitor; however, when we competed the “hot” 5hmC probe in
this complex with increasing concentrations of “cold” probe containing either C,
5mC or 5hmC, the latter probe competed out the hot 5hmC probe slightly better
than the others (Fig 3.1.C). This effect was especially clear when the competitor
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concentration was 150-fold of labeled probe. Although this specificity seemed
subtle under our assay conditions, it was robust and reproducible. Hence we
attempted to biochemically purify and identify the proteins that cause this specific
activity, with the expectation of finding another decoding mechanism for 5hmC in
the brain.

III.II. Biochemical purification of 5-hmC-specific complex
!

First we prepared nuclear extract from 80 rat cerebella and fractionated it

over a column coated with heparin, which has been used as a biomimetic
polymer of DNA because it is a highly sulfated glycosaminoglycan and a linear
negatively charged polymer with a size ranging from 5-30 kDa (Kiss, Kakkar et
al. 1976; Farooqui 1980). Therefore heparin chromatography is a suitable way to
separate DNA-binding proteins from the rest on nuclear proteins. Thus, highly
concentrated nuclear extracts were applied on a heparin column at physiological
conditions and extensively washed. The bound proteins were eluted by gradually
increasing the salt concentration from 0.15 to 1 molar (1M), collected in
sequential fractions and assayed for their DNA binding.
In our initial gradient elution (Δ[KCl] = 43 mM/min), we observed a 5hmC-specific
complex that eluted at salt concentrations 0.4-0.55M. The complex resulted
EMSA shift of similar distance from the free probe as the shift observed in NE
(Fig 3.2.A). The signal intensity of this 5hmC-specific complex in fraction 28 was
two-fold of 5mC-containing complex (Fig 3.2.B). When we used a less steep
gradient (Δ[KCl] = 20 mM/min), we observed a second, higher mobility complex
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that eluted at lower salt concentrations, at 0.27-0.39 M (Fig 3.2.C), that was not
present when the probe was made with 5mC. Since the mobility of both
complexes were very close, it could be possible that the initial 5hmC activity we
observed was made up of more than one species. Since we could biochemically
separate these two species, we decided to purify them in parallel. A schematic
flow of our biochemical purification is shown in Fig 3.3.A. Basically, we pooled
fractions containing the later eluting complex (fractions 28 to 34 in 3.2.C, referred
as complex A) and fractions containing the earlier eluting complex (fractions
24-27, referred as complex B) separately. We applied both mixtures sequentially
on a size exclusion column. The fractions that still showed the specific activity
were once more pooled for each complex and applied on affinity columns that
were coated with DNA containing 5hmC; and finally the bound proteins were
eluted with a steep salt gradient. The fractions with the specific activity were
pooled, concentrated and separated in SDS PAGE. Finally the bands that were
visible after Coomassie stain were excised and identified by MS. The pooled
fractions at each purification step were analyzed by SDS PAGE followed by
Coomassie staining (Fig 3.3.B) as a confirmation after each purification step.
Finally, by mass pectrometry based database search, the proteins that co-purified
with complex A were identified as Purine-rich element binding proteins, Purα and
Purβ, in addition to Parp1 and Snrnp200 (Fig 3.3.C); while complex B co-eluted
with a family of heterogenous nuclear ribonucleoprotein AB (hnrnpAB), hnrnpD,
hnrnpR and hnrnpU (Fig 3.3.D).
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III.III. 5-hmC-specific complex contains Purα
!

Previously, in our experiments, unlike MeCP2 NT (23 kDa), full-length

MeCP2 (70 kDa) failed to enter the native gel from the wells. It is likely that fulllength MeCP2 is too large to penetrate through the pores of the acrylamide
matrix, though its intrinsic disorder may be a factor as well. Based on this
criterion, we focused on Purα, Purβ, hnrnpAB and hnrnpD, all of which are less
than 50kDa. To check the presence of these proteins in the 5hmC-specific
complex that we originally observed, we first incubated the extract with
antibodies against these proteins, then the competitor and the radioactive probe.
The complex was clearly depleted by anti-Purα antibody without affecting other
complexes within the lane, whereas the other antibodies did not show reactivity
(Fig 3.4.A). Although this result gave us confidence that Purα was the strongest
candidate to be the 5hmC-specific protein, it was not enough to exclude the
possibility that other proteins might be involved, too. This could be due simply to
low affinity of antibodies. Indeed, in our in vitro experiments, anti-Purβ antibody
failed to deplete the recombinant Purβ/5hmC complexes (data not shown); we
interpret the supershift assays using this antibody as inconclusive. When we
reacted the anti-Purα antibody with the purified complex A, we observed the
supershift, as expected (Fig 3.4.B); however, the specificity of the complex was
compromised during purification.
As an additional control, we applied nuclear extracts directly onto DNA affinity
column containing 5hmC and eluted at Δ[KCl] = 20 mM/min. After visual
inspection fractions in SDS PAGE, we pooled fractions that contain similar
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protein composition (Fig 3.5.A) and analyzed the binding of these pooled
fractions to DNA as previously by Southern blot using radioactive probes
containing C, 5mC and 5hmC (Fig 3.5.B) and EMSA (Fig 3.5.C). The Southern
blots did not reveal any 5hmC-specific bands; however, we observed a protein in
fraction pools 41-44 and 45-49 with specific binding to 5mC and 5hmC containing
DNA at the size of MeCP2. Indeed, by MS we identified the protein band (marked
with red dot adjacent to number 1) to be MeCP2, confirming our previous results.
Additionally, the band of the correct size but in early fractions did not contain any
MeCP2. The bands adjacent to numbers 2 and 3 were identified as Purα and
Purβ, respectively. Intriguingly, the bands of this size at pool 37-40 contained
several Hnrnps and low amounts of Purα or Purβ. Fraction 41-44 contained
similar amounts of Hnrnps and Purα or Purβ, whereas fraction 45-49 contained
exclusively Purα or Purβ. The increase in the amounts of Pur proteins in the later
fractions as the elution conditions get more stringent also tracks with the specific
activity observed in the EMSA, confirming that Pur proteins are most likely the
major components of the 5hmC-specific complex. The proteins marked with 4
and 5 are identified as several subclasses of Histone H1.
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III.IV. Binding of recombinant hnrnps to 5hmC
!

Although hnrnps are first described as a family of proteins, which bound

nascent RNA transcripts (Choi and Dreyfuss 1984), their functions vary greatly
(Han, Tang et al. 2010). HnrnpAB and D have also been implicated in DNA-linked
processes as well, such as telomere maintenance (Ford, Wright et al. 2002; Chai,
Zheng et al. 2003), transcription (Chai, Zheng et al. 2003) and replication
(Campillos, Lamas et al. 2003). We expected the hnrnps to be a false positive;
given that they are predominantly involved in RNA processes, combined with our
findings that (1) their amounts of hnrnps negatively correlated with the specific
activity in fractions eluted from the DNA column, (2) the specific complex reacts
with anti-Purα antibody and not with anit-hnrnp antibodies, and (3) in the
competition assays the complex A (containing Pur proteins) behaves like the
5hmC-specific complex in the crude extract. To confirm that hnrnps were indeed
nonspecific, hnrnpAB and hnrnpD were produced in E.coli and purified using a
His tag (Fig 3.6.A, left panel). To our surprise, when we assayed the DNA binding
characteristics of these proteins at very low concentrations, both proteins formed
a weak 5hmC-specific low mobility complex in presence of competitor DNA (Fig
3.6.B). The 5hmC-dependent signal of hnrnpAB was 4-fold of both C- and 5mCdependent signals (Fig 3.6.C, left), whereas in the case of hnrnpD this effect was
around 2-fold (Fig 3.6.C, right). Interestingly, as the concentration of the hnrnpAB
increased, the low mobility complex disappeared (Fig 3.6.C, black arrow) and a
higher mobility complex started to appear (Fig 3.6.C, red arrow), the intensity of
which was independent of the DNA modification. We postulated that the basis of
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these two different complexes with different binding characteristics might be
explained by the structural properties of these proteins: hnrnpAB and D contain
two RNA recognition (RRM) domains (Hoffman, Query et al. 1991). RRM1 is
highly conserved between hnrnpAB and hnrnpD, and so is RRM2; whereas the
homology between RRM1 and RRM2 is much lower. It is then possible that
RRM1 and 2 might have different characteristics for nucleic acid binding.
It is possible that the low mobility complex is formed when the probe is in excess
and thus both RRMs are occupied by one radioactive probe; whereas when only
on RRM is bound by a probe, then a higher mobility complex can be observed. If
the remaining RRM is bound by the nonspecific competitor, the mobility of the
complex will vary, causing a background smear. To directly address this issue, we
produced recombinant RRM1 and RRM2 of both hnrnps (Fig 3.6.A, right panel)
and assayed their DNA binding. Their DNA binding efficiency was significantly
reduced, but preliminary results indicated that RRM1 of hnrpAB is marginally
more specific to 5hmC-containing DNA (Fig 3.6.E).
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III.V. Binding of recombinant Purs to 5hmC
!

Purα together with Purβ and two isoforms of Purγ constitute a distinct and

highly conserved class of PUR family that has been implicated in multiple roles in
cellular and viral regulation of nucleic acids, including some neuronal genes in
higher eukaryotes (Gallia, Johnson et al. 2000; White, Johnson et al. 2009). Purα
expression increases during development with highest levels observed in bodies
and dendrites in PCs, where the highest 5hmC levels also are observed
(Kriaucionis and Heintz 2009). Purα-deficient mice die after birth with severe
neurological pathologies (Khalili, Del Valle et al. 2003). They also are linked to
leukemia (Lezon-Geyda, Najfeld et al. 2001), just as Tet genes (Kosmider,
Delabesse et al. 2011; Lorsbach, Moore et al. 2003). Therefore Purα might be an
important player in neural epigenetic regulatory mechanisms.
Although not much is known about in vivo functions of Purβ, in situ hybridization
data show that it is highly enriched in PCs as well (http://mouse.brain-map.org/).
To have insight into their binding characteristics, we produced recombinant
proteins in bacteria (Fig 3.7.A). We observed some DNA binding activity by each
of these proteins with marginal preference for 5hmC (Fig 3.7.B). Recombinant
Purα, when bound to unmodified or methylated probe formed two complexes with
different mobilities. When unmodified, these complexed were of equal intensity.
Upon methylation, the lower mobility complex seemed to be conserved whereas
the level of the higher mobility complex decreased, and this complex also
migrated a little faster than the corresponding complex with C-containing probe.
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In contrast, Purα formed a single lower mobility complex upon binding to
hydroxymethylated DNA, which seemed to have higher levels compared to the
other lanes, although this might simply be due to co-migration of two distinct
complexes. Purβ forms a smear of low-mobility complexes with unmodified DNA,
and the binding is much weaker when DNA is methylated. The intensity of Purβ/
5hmC smear was slightly higher compared to Purβ/C smear by visual inspection.
We then quantified the signal intensities of the lowest mobility complex of each
sample and derived a binding curve (Fig 3.7.C). The preference for 5hmC of both
proteins was < 2-fold compared to other probes. Even at highest concentrations,
these proteins failed to produce an SPR response on the DNA-coated surfaces
(data not shown).
We suspected that the loss in specificity might be due to a co-factor that is not
present in the in vitro binding reaction. Therefore we included increasing
amounts of crude extract; however, it did not make a difference in the binding
characteristics of these proteins (data not shown). Since Purα and Purβ can
strongly interact with each other in a DNA-dependent as well as DNAindependent way (Kelm, Cogan et al. 1999), we have also combined both
proteins in the expectation that they might show cooperativity; unfortunately,
incubation of these proteins prior to introduction of nucleic acid did not make a
difference (data not shown). Endogenous Purs might be post-translationally
modified in the 5hmC-specific complex, whereas the bacterially expressed
recombinant proteins are not. Another alternative is that the crude extract
contains a variety of proteins that bind unmodified DNA and others that recognize
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5mC-containing DNA and do not give access to Pur proteins; however, 5hmC is
not preferred by many proteins so they occupy 5hmC sites. Under artificial
conditions they are not selective for DNA modification. It is possible that these
complexes also form with DNA containing C or 5mC in the nuclear extracts;
however, they are bound by additional factors and migrate at much lower rates
and therefore are not visible at the location we detect the 5hmC-dependent
complex.

III.VI. Support for strand separation by Purs
Pur proteins consist of a glycine-rich flexible N terminus, a central nucleic acid
binding core, with highest sequence conservation, and a C-terminal region, that
is thought to be involved in protein interactions. The two nearly-identical PUR
repeats interact with each other to form a PUR domain, which form two
independent DNA binding surfaces, whereas a third PUR repeat facilitates the
dimerization of Purα (Graebsch, Roche et al. 2009). The Pur proteins have been
characterized by their binding to single-stranded DNA (ssDNA), double-stranded
DNA (dsDNA), and ssRNA with a preference for GGN-repeats (Knapp, Ramsey
et al. 2006). Purα is able to unwind duplex DNA, displacing the pyrimidine-rich
strand while maintaining contact with the purine-rich strand (Wortman, Johnson
et al. 2005). Since 5hmC might destabilize the duplex structure (Thalhammer,
Hansen et al. 2011) we next asked whether the preference for 5hmC could be
simply because this modification expedites the strand separation for the PUR
proteins. To test this idea we competed the “hot” 128 bp probe with short,
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unlabeled and unmodifed ssDNA sequences (1-49, 38-86, 80-128 of radioactive
probe). Indeed, only couple strands, but not their complimentary strand, could
abolish binding to 5hmC even at very low concentrations (Fig 3.7.D). Their effect
was weaker when the complimentary strand was added to the reaction, indicating
that sequence-specific ssDNA binding is an essential mechanism for the DNA
recognition of Pur proteins, although one strand did not contain a GGN repeat.
Together this study proposes several candidates that might recognize 5hmC in
vivo; however, their biological relevance still remains unclear.

III.VI. Discussion
!

The study presented here identifies a 5hmC-specific complex in the

nuclear extracts from cerebellum and introduces new candidates for the
decoding of 5hmC code in the brain. Although there is a lot to be done to
characterize the biological function of these proteins upon binding to 5hmC, we
present some convincing evidence that Purα is an integral component of this
complex. The significant role and abundance of both 5hmC and Purα in PCs
(Kriaucionis and Heintz 2009), combined with our results showing that in crude
nuclear extracts there is a Purα-complex that associates with hydroxymethylated
DNA up to 10-fold more avidly than unmodified or methylated DNA, suggest that
this interaction might be crucial for neuronal function. In the brain Purα is found
at high levels in Purkinje cells (Khalili, Del Valle et al. 2003; Hokkanen, Feldmann
et al. 2011) with a peak of expression during critical periods of brain
development, and in Purα

-/-

mice showing neurodevelopmental defects (Khalili,
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Del Valle et al. 2003). Also high levels of 5hmC are present in both developing
and adult brains (Ruzov, Tsenkina et al. 2011; Szulwach, Li et al. 2011). Together
these data suggest a complex yet significant role for Purα protein in the brain.
• Mysterious Purα

Although we were able to discover a Purα-complex with preference for 5hmCcontaining DNA, we still donʼt know if hydroxymethylated sites are occupied by
this complex in vivo and more importantly what the downstream events are. We
also donʼt know the other components of this complex, if there are any. To
answer the first question, a cell-specific genome-wide ChIP-Seq experiment for
Purα can be performed. Yet we still donʼt know how this interaction is functionally
interpreted by Purα, since the functional data of Purα is controversial. It has been
shown to function as a transcriptional activator (Haas, Gordon et al. 1993; Haas,
Thatikunta et al. 1995; Zambrano, De Renzis et al. 1997) and repressor
(Penberthy, Zhao et al. 2004; Subramanian, Polikandriotis et al. 2004), in
addition to its various roles in both RNA- and DNA-dependent processes (Li,
Koike et al. 2001; White, Johnson et al. 2009), including DNA repair (Kaminski,
Cheeseboro et al. 2010). This data makes the interpretation of 5hmC-dependent
role of Purα difficult to judge. It is likely that Purβ is a component to the Purαcomplex, since Purα and Purβ can strongly interact with each other (Kelm,
Cogan et al. 1999). Hnrnps may also be included, since their interaction with Pur
proteins has been previously suggested (Li, Koike et al. 2001).
Moreover the binding of recombinant or purified Purα, as well as Purβ and
hnrnps, to 5hmC was compromised. This may be due to limitations of in vitro
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reconstitution assays. First, the recombinant proteins expressed in bacteria lack
posttranslational modifications. This problem can be solved by switching to a
mammalian expression system. Secondly, both recombinant and purified proteins
were stripped from any co-factors or other binding partners. To overcome this we
have supplemented the reaction with nuclear extract but did not observe any
recovery. On the other hand, if there is a dose dependence then this strategy can
be improved by first depleting the endogenous Pur proteins using an antibody,
and then adding this to the recombinant Purα. In the assay conditions these
proteins are very labile. In addition, with each purification step, the addition of
albumin was increasingly necessary, indicative of high background non-specific
binding.
• Specific, not specific

Although this complex appears specific in the crude extract, we could not detect
a strong preference for recombinant Purα to 5hmC in vitro. Although it is highly
probable that the in vitro conditions failed to reproduce the endogenous
environment, we also have to consider the possibility that Purα-complex does not
bind 5hmC preferentially. We propose several explanations for this assumption:
First, the fact that mammalian proteome contains thousands of DNA binding
proteins (Kadonaga 2004), whereas only a few proteins are known to specifically
recognize methylated sequences (Ballestar and Wolffe 2001; Fournier, Sasai et
al. 2012). Although some DNA-binding proteins still may recognize their cognate
DNA sequences when they are modified, it is reasonable to assume that a
substantial fraction of these are displaced upon DNA modifications within their
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binding sites. Therefore, even if in vitro binding of a protein to its target shows
only subtle changes at different modification states, these may be translated to in
vivo occupation of the majority of hydroxymethylated sites by such factors, since
there is much bigger competition for an unmodified site. Since the nuclear extract
represents a system that is close to the in vivo environment, it is very likely that
this interaction has biological relevance.
A second probable explanation is that the complex forms with each modification
of DNA. However when it contains unmodified or methylated DNA, it is bound by
additional factors and therefore it does not have the same mobility. If 5hmC
causes formation of a complex that has different protein composition, this is still
significant since it can potentially explain the downstream events following the
formation of this complex, the composition of which differs depending on the
DNA modification. Finally it is also possible that one probe (128 bp) can
accommodate more than one complex independently.
• The strand-separation hypothesis

A noteworthy but simple model for the preferential interaction between 5hmC and
Pur proteins is that the hydroxymethylated DNA is energetically “cheaper” for
strand-separation by Pur proteins and therefore the binding kinetics are
enhanced. If Purα is able to unwind duplex DNA to maintain contact with the
purine-rich strand (Wortman, Johnson et al. 2005), then the pyrimidine-rich
strand might be stabilized by another protein in the nuclear extract. When this
protein is not present after purification of the reconstituted system, the unbound
strand might be energetically too “costly” to maintain the preferential binding.
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Indeed, an example for such interaction has been previously demonstrated,
where Pur proteins strongly interacted with a pyrimidine-rich DNA-binding
protein, MSY1 (Kelm, Cogan et al. 1999). Although this interaction was
reproduced in the absence of DNA as well, it does not exclude the possibility that
this kind of communication between proteins might be a significant biological
process. However this implies that as an ssDNA competitor abolishes binding as
in Fig 3.6.D, the complimentary strand then should then have the opposite effect,
since it would stabilize the displaced strand of the original probe. This has not
been observed in our experiments. Strand separation model also could explain
the different mobilities of Pur/C, Pur/5mC and Pur/5hmC complexes. These could
be simply two populations where the Pur protein is bound to one strand or the
complimentary. Indeed, the molecular weight between strands is 0.27 kDa. Since
the mobility in the native gel might depend on factors other than molecular size,
this small difference might explain this phenomenon.
• What else is out there and how do we search?

In this study we identified a Purα-complex that binds 5hmC specifically. Yet our
biochemical understanding of this complex is still limited and we do not have
information on the functional meaning of this interaction. In addition, we still donʼt
know which proteins occupy the rest of the hydroxymethylated sites, or whether
they are depleted of proteins. We can improve and extend our strategies to find
new candidates: First there is a large population of proteins that remain tightly
bound to the chromatin after salt extraction and thus not subject to our analysis,
whereas high salt concentration may be disruptive for certain proteins. Secondly,
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the ionic conditions in gel shift assays might cause interactions to be lost. By
enzymatic degradation of nucleic acids to get nuclear proteins, combined with
further extending the detection methods more candidates may be screened.
Finally, using different sequences as DNA baits that are modified in various
contexts can increase the screening efficiency.
Identifying the readers of the 5hmC code will contribute greatly to the
understanding of neuronal epigenetics, although it is also possible that 5hmC
simply modifies the physical properties of the duplex DNA, changing the structure
of chromatin, re-arranging nucleosomes, displacing methylation-specific factors
or increasing accessibility to proteins that bind ssDNA, which includes RNA
Polymerase II. To decipher the 5hmC code and understand its true meaning, our
studies need to encompass many possible scenarios, some of which may be
occurring in concert. However in the words of Albert Einstein “[A]s our circle of
knowledge expands, so does the circumference of darkness surrounding it.”
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Materials and Methods
Preparation of Probes
!

C, 5mC and 5hmC probes were prepared using either unmodified dCTP

(New England Biolabs), 5ʼ-methylated dCTP (Trilink Biotechnologies, San Diego,
CA, USA) or 5ʼ-hydroxymethylated dCTP (Bioline, Taunton, MA, USA), along with
dATP, dTTP and dGTP (New England Biolabs). A 120 bp region of mouse BDNF
promoter was amplified with ChoiceTaq (Denville, South Plainfield, NJ, USA)
according to manufacturerʼs recommendations using 5ʼ-biotinylated or 5ʼunmodified forward primers and 5ʼ-unmodified reverse primers (Genelink,
Hawthorne, NY, USA) listed below. For CG-rich probe we amplified a 200 bp
region of the pUC plasmid (Invitrogen). Probes were purified via Qiaquick PCR
Purification Columns (Qiagen). 1 pmol of probe was end-labeled with 1 or 10 uCi
of γ-P32 dATP (Perkin Elmer, Waltham, MA, USA) using T4 Polynucleotide
Kinase (New England Biolabs) for 45 min at 37°C and purified using Illustra
ProbeQuant G-50 Micro Columns (GE Healthcare, Little Chalfont, UK).

32P

was

counted in scintillation fluid Ready Safe (Beckman Coulter) in 1209 Rackbeta
scintillation counter (LKB-Wallac Pharmacia, Turku, Finland).

primer

sequence

BDNF F

GCGTGAATTTGCTAGGACTGG

BDNF R
CG-rich F
CG-rich R
probe 1 (p1) F
probe 1 (p1) R

GAATTACCAGAATCAGAATTCCG
GTGAGCTAACTCACATTAATTG
TGCTCACATGTTCTTTCCTG
GCCCATTCTTTCTTGATAGATTTTAGTTGTTCAAC
TGAGCATCCTGGCGAGCATAG
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probe 2 (p2) F
probe 2 (p2) R
probe 3 (p3) F
probe 3 (p3) R
single-site F
single-site R

GCCCACAATAAACCAGCCACTTACCAG

CGCt

AATAAAACATCTACAAAATCAACCCTAAAACcgcTTTAATAGGAAAGATGTATAT
TTTAAATGG
AATAAAACATCTACAAAATCAACCCTAAAACcacTTTAATAGGAAAGATGTATAT
TTTAAATGG
AATAAAACATCTACAAAATCAACCCTAAAACcccTTTAATAGGAAAGATGTATAT
TTTAAATGG
AATAAAACATCTACAAAATCAACCCTAAAACctcTTTAATAGGAAAGATGTATAT
TTTAAATGG
AATAAAACATCTACAAAATCAACCCTAAAACcgaTTTAATAGGAAAGATGTATAT
TTTAAATGG
AATAAAACATCTACAAAATCAACCCTAAAACcaaTTTAATAGGAAAGATGTATAT
TTTAAATGG
AATAAAACATCTACAAAATCAACCCTAAAACcgTTTAATAGGAAAGATGTATATT
TTAAATGG
AATAAAACATCTACAAAATCAACCCTAAAACcaTTTAATAGGAAAGATGTATATT
TTAAATGG
GCGTGAATTTGCTAGGACTGGAAGTGAAAACATCTACAAAGCATGCAAT

CACt
CCCt
CTCt
CGA
CAA
CGT
CAT
1+
12+
23+
3-

GGGAGATGTTCTGGCCTCTCAG
GTAAGCTGATGGAAAACTGCTGTTG
AGCCAACTCTCTAAGAGATGGACCTCAC
CATGAATAAAACATCTACAAAATCAACCCTAAAAC
TCGACCATTTAAAATATACATCTTTCCTATTAAAC

ATTGCATGCTTTGTAGATGTTTTCACTTCCAGTCCTAGCAAATTC ACGC
CAAAGCATGCAATGCCCTGGAACGGAATTCTTCTAATAAAAGATGTATC
GATACATCTTTTATTAGAAGAATTCCGTTCCAGGGCATTGCATGCTTTG
ATAAAAGATGTATCATTTTAAATGCGCGGAATTCTGATTCTGGTAATTC
GAATTACCAGAATCAGAATTCCGCGCATTTAAAATGATACATCTTTTAT

Nuclear protein extracts from cerebella
!

Nuclear extracts were prepared from 80 frozen rat cerebella (Pel-Freez,

Rogers, AR, USA) as previously described (Klose and Bird 2004). Briefly, rat
brains were diluted 5 volumes to 1 in ice-cold Buffer A containing 10 mM Hepes
pH 7.5, 25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2 M
sucrose, 10% glycerol, and Halt Protease and Phosphatase Inhibitor Cocktail
(Pierce Biotechnology, Rockford, IL, USA) followed by homogenization in a 60
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mL Dounce (Bronwill Scientific Inc., Rochester, NY) on Glas-Col Tissue
Homogenizer (Cole-Parmer, Vernon Hills, IL, USA) (5 strokes at 4,000 rpm). The
homogenate was layered onto a 10 mL cushion of the Buffer A and centrifuged in
pre-chilled SW2 (Beckman Coulter) rotor at 24,000 revolutions per minute (rpm)
in Beckman XL-70 ultracentrifuge for 1 hour at 2 °C. Recovered nuclei were
incubated in 5 volumes of Buffer B containing 20 mM Hepes (pH 7.9), 150 mM
KCl, 1 mM EDTA, 0.5 mM DTT, Halt Protease and Phosphatase Inhibitor Cocktail
on ice 2 min and then resuspended. The nuclei were counted by Neubauer
haemocytometer (Hausser Scientific, Horsham, PA, USA). The nuclear proteins
were extracted by stepwise addition of 3M KCl until a final concentration of 400
mM. The extraction was allowed to proceed for 20 min on ice, and then the nuclei
were pelleted at 13,000 rpm for 10 min at 4°C. The supernatant was dialyzed in
Slide-A-Lyzer cassettes with 10 kDa molecular weight cutoff (Pierce) overnight at
4°C against Buffer B. The protein concentration was measured by Quick Start
Bradford Assay (BioRad) according to manufacturerʼs instructions. For fast
protein liquid chromatography, 10 mL of the dilate was collected and centrifuged
5 min at 14,000 rpm. The cleared lysate then was concentrated in Amicon15 10K
MWCO (Millipore) 20 min at 4,000 rpm at 4°C or until the extract is down to 4 mL.
Alternatively, nuclear extracts were prepared from 10 wild type (WT) or ECP2 KO
mice using SW41 rotor with a 2 mL cushion of Buffer A.

5hmC affinity pull-down
"

10 ug of 5ʼ-biotinylated C, 5mC or 5hmC BDNF probe was immobilized on
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Dynabeads M-280 Streptavidin (Invitrogen) following manufacturerʼs
recommendations and incubated with 2 mg of nuclear extract in presence of 1
mg of poly-dIdC competitor (Sigma Aldrich) in Buffer B supplemented with 1%
Triton X-100 (Sigma Aldrich) 1 hour at room temperature. The isolated proteins
were washed extensively and eluted in 1X LDS Sample Buffer (Invitrogen) under
reducing conditions, separated by gel electrophoresis in 4-12% gradient BisTris
Gels (Invitrogen) and stained by GelCode Blue (Pierce) or Silver Stain Kit
(Pierce). Protein bands were excised from a GelCode stained gel and analyzed
by mass spectrometry (MS). Alternatively, nuclear extracts prepared from WT or
KO mice were incubated with magnetic beads coated with 5ʼ-Biotinylated CG-rich
probes. Nuclei from Mecp2tm1.1Bird hemizygous males were a gift from Dr Adrian
Bird.

MeCP2 immunoprecipitation
"

40 ug of 5ʼ-biotinylated probe containing CpG, 5mCpG, 5hmCpG, CpA,

5mCpA and 5hmCpA was immobilized on Dynabeads M-280 Streptavidin
(Invitrogen) following manufacturerʼs recommendations. 10 mg of nuclear extract
supplemented with 0.5 mg of poly-dIdC competitor (Sigma Aldrich) in Buffer B
was incubated with the DNA-coated beads for 1 hour at room temperature. The
isolated proteins were washed extensively and eluted for 30 min in Buffer N
containing 400 mM NaCl, 50 mM Hepes pH 7.9, 1 mM EDTA, 10 mM DTT, 0.5%
SDS and 10 units/ml of Benzonase (Sigma). 50 ug of anti-MeCP2 antibody (Cell
Signaling) was coupled to Dynabeads Protein A (Invitrogen) in Buffer B
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supplemented with 0.5% Igepal (Sigma) according to manufacturerʼs
recommendations. The eluates in Buffer N were diluted 1:5 in Buffer B and
incubated with MeCP2-coated beads for 2 hours at room temperature. The
proteins bound to beads were eluted in 1X LDS Sample Buffer (Invitrogen) under
reducing conditions, separated by gel electrophoresis in 4-12% gradient BisTris
Gels (Invitrogen) and assayed by Western blotting.

Western blotting
!

For Western blotting, the extracts denatured in sample buffer (Invitrogen)

under reducing conditions, and eluates prepared as described above, were
separated on a pre-cast Bis-Tris SDS-gel (Invitrogen) via electrophoresis and
transferred on a PVDF-membrane (Biorad). The membrane was blotted with
primary antibodies, anti-MeCP2 (Upstate) antibody in combination with horseradish-peroxidase-conjugated secondary antibody (Pierce) or antiphosphoserine-HRP (Abcam). The chemiluminescence was detected by the
application of the ECL substrate (Pierce).

Southwestern Blotting
!

Nuclear extract (isolated as described above) was separated on duplicate

gels and transferred to PVDF membranes (BioRad) in Mini Trans-Blot
Electrophoretic Transfer Cell (BioRad) at 100 V for 2 hours at room temperature
and assayed for DNA binding as previously described (Campoy, Meehan et al.
1995). The blotted proteins were re-natured by immersing the blot in Buffer B
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with 6 M guanidine HCl, which was then serially diluted to 3, 1.5, 0.75, 0.375,
0.188, and 0.094 M using binding Buffer B with incubation at 4°C for 5 min each
time. The blot was blocked at room temperature for 30 min in Buffer B containing
5% non-fat milk, then incubated with 105 cpm/mL CG-rich 5mC or 5hmC probes
with 10 ug/mL poly-dIdC for 2 hours at room temperature, extensively washed
with Buffer B and air-dried. The autoradiography was measured by exposing a
storage phosphor screen (Molecular Dynamics, Sunnyvale, CA) that was
scanned by Typhoon Imager (GE Healthcare) and analyzed by ImageJ software.

Expression and purification of recombinant proteins
!

cDNA clones of human MeCP2, and MBD family of proteins were

purchased from Open Biosystems (Lafayette, CO) and cloned into pet28a vector
(Novagen, Madison, WI, USA) using primers listed below with NdeI and XhoI
(NEB) restriction sites.

primer
MeCP2 NT
(aa 1-205) F
MeCP2 NT
(aa 1-205) R
MeCP2 MBD
(aa 77-167) F
MeCP2 MBD
(aa 77-167) R

sequence
ATGGTAGCTGGGATGTTAGGGCTCAGGGAAG
AGACCCAAGGCGGCCACGTCA
GCTACCGGACTCAGATCTCGAGCTCAACGCCACCATGGCTTCTGCCT
CCCCCAAACAGCG
CCGCGGTACCGTCGACTGCAGAATTCGACCGGGAGGGGCTCCCTCT
CCC

MeCP2 (aa 1-486) F ATGGTAGCTGGGATGTTAGGGCTCAGGGAAG
MeCP2 (aa 1-486) R GCTAACTCTCTCGGTCACGGGCGTCCGGCTGTCCAC
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MBD1 (aa 1-144) F

ATGGCTGAGGACTGGCTGGACTGCCCG

MBD1 (aa 1-144) R

GCCATCCCCTGAGAAGCTGATTCCACAGTTCTCACAGCAC
ATGGCCACGGAGAGCGGGAAGAGGATGGATTGCCCGGCCCTCCCCC

MBD2 (aa 141-319) F CCG
MBD2 (aa 141-319) R CTCATCATTGCTACCTGGACCAACTCCTTGAAGACCTTTGGGTAG
MBD3 (aa 1-259) F

ATGGAGCGGAAGAGCCCGAGCGGGAAGAAGTTC

MBD3 (aa 1-259) R

GTGCTCCATCTCCGGGTCCGGGTCG

MBD4 (aa 1-197) F

ATGGGCACGACTGGGCTGGAGAGTCTGAGTCTG

MBD4 (aa 1-197) R

CTCTGAACTACTACTTGGCGGCATAAACACATCCTTTTTGC

L100V Rin

GTGTCCAGCCTTCAGGCACGGTGGG

L100V Fin

GTGCCTGAAGGCTGGACACGGAAGC

D121G Rin

CTTTTCCCTGGGGATTGATCAAATACACACCATACTTCCCAG

D121G Fin

GTGTGTATTTGATCAATCCCCAGGGAAAAGCCTTTC

R133H Rin

ACTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC

R133H Fin

CGAAGTACGCAATCAACTCCACTTTAGAGTGAAAGGCTTTTC

R133C Rin

TGCTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAG

R133C Fin

GTACGCAATCAACTCCACTTTAGAGCAAAAGGCTTTTC

S134C Rin

GTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGC

S134C Fin

CGAAGTACGCAATCAACTCCACTTTACAGCGAAAGGC

S134F Rin

TTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC

S134F Fin

CTTTTCGAAGTACGCAATCAACTCCACTTTAAAGCGAAAGGCTTTTC

E137G Rin

CTACCTTTTCGAAGTACGCAATCAACCCCACTTTAGAG

E137G Fin

GGTTGATTGCGTACTTCGAAAAGGTAGGCGACAC

A140V Rin

GTGTCGCCTACCTTTTCGAAGTACACAATCAACTCCAC

A140V Fin

TGTACTTCGAAAAGGTAGGCGACACATCCCTGGAC

R133M Rin

GAAGTACGCAATCAACTCCACTTTAGACATAAAGGCTTTTC

R133M Fin

ATGTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC

R133K Rin

GAAGTACGCAATCAACTCCACTTTAGACTTAAAGGCTTTTC

R133K Fin

AAGTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC

R133E Rin

GAAGTACGCAATCAACTCCACTTTAGACTCAAAGGCTTTTC

R133E Fin

GAGTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC
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R133S Rin

GAAGTACGCAATCAACTCCACTTTAGAGCTAAAGGCTTTTC

R133S Fin

AGCTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC

purα F

ATGGCGGACCGAGACAGCGGC

purα R

ATCTTCTTCCCCTTCTTCCTCACCCTG

purβ F

GCGGACGGCGACAGCGGC

purβ R

ATCCTCATCCACCTCCTCACCCTC

hnrnp AB F

ATGTCGGACGCGGCTGAGGAGC

hnrnp AB R

GTATGGCTTGTAGTTATTCTGATGAC

hnrnp D F

ATGTCGGAGGAGCAGTTCGGAG

hnrnp D R

GTATGGTTTGTAGCTATTTTGATGTCCACCTCG

hnrnp AB R1 F

ATGTCGGACGCGGCTGAGGAGC

hnrnp AB R1 R

CATAGCCATAGCCTTTTTAGGGTC

hnrnp AB R2 F

ATGGCTATGAAGAAGGACCCTG

hnrnp AB R2 R

GTATGGCTTGTAGTTATTCTGATGAC

hnrnp D R1 F

ATGTCGGAGGAGCAGTTCGGAG

hnrnp D R1 R

TCTTTTGTTTTCATGGCTTTG

hnrnp D R2 F

GAGCCTGTCAAAAAAATTTTTG

hnrnp D R2 R

GTATGGTTTGTAGCTATTTTGATGTCCACCTCG

The C-terminally 6-His tagged recombinant proteins were expressed in BL21
strain of E. coli (Invitrogen) in Overnight Express Autoinduction System (EMD
Millipore, Billerica, MA, USA), purified using Ni-NTA Spin columns (Qiagen)
according to manufacturerʼs recommendations and dialyzed against Buffer B
supplemented with 10% glycerol. The protein concentration was measured by
Quick Start Bradford Assay (BioRad).
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Electrophoretic mobility shift assay (EMSA)
!

Unless stated otherwise, 1 pmol of MeCP2 (aa 1-205), 1.2 pmol of MBD1,

0.5 pmol of MBD2, 50 pmol of MBD3 or 2.5 pmol of MBD4 was incubated with 10
fmol of

32P-end-labeled

C, 5mC or 5hmC BDNF probe in presence of 1 µg of

pdIdC in Buffer B supplemented with 5% Ficoll for 30 min at room temperature
(RT). 10 μL of the binding reaction was electrophoresed in native 6% 29:1
acrylamide:bis-acrylamide gel in 0.5 % TBE buffer at 4°C for 2-4 h. The gels were
then dried in vacuum (Fisher Scientific, Hampton, NH, USA) for 1 h at 70°C,
exposed to a storage phosphor screen (Molecular Dynamics) and scanned by
Typhoon Imager (GE Healthcare). For assays with crude nuclear extracts,
concentrations ranging from 60 ng to 2 μg were first incubated with 5-10 μgs of
polydIdC for 10 min at RT and then with 2.5-10 fmoles of radioactive probe. For
heparin fractions, a total of 4 μL of the pool, 2.5 μg polydIdC and 2.5 fmoles of
probe was used. For size-exclusion and affinity column fractions, a total of 20 μL
of the pool was used with 0.5 μg polydIdC and 5 fmoles of probe.

Surface Plasmon Resonance
!

Four flow cells (Fc) of Streptavidin (SA)-Sensor Chips (GE Healthcare)

were cleaned with 3, 1-min pulses of 1M NaCl in 50mM NaOH in Biacore 3000
(GE Healthcare). 5ʼ-biotinylated C, 5mC and 5hmC BDNF probes were injected
onto Fc 2, 3 and 4, respectively, at 2 μL/min in Buffer B until SPR response
increased by 500(+/-25) Resonance Units (RU). Fc 1 was immobilized with 2 mM
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Biotin to serve as reference cell. 8-12 serial dilutions of protein samples within
0.01 Kd to 10 Kd range in Buffer B supplemented with 0.02% Tween and 50 ng/
μL poly-dIdC were injected onto each Fc in parallel at 30 μL/min for 3 min. The
surfaces were regenerated by 1 min injection of Buffer B with 1.5 M KCl (Buffer
C). The change in SPR response with respect to reference cell 5 seconds before
the end of injection was recorded for steady state analysis. Each run was
performed in duplicates and each experiment was repeated with at least 4
samples of each protein preparation on two independently prepared surfaces.
Bmax values and their standard error were automatically extracted in GraphPad
Prism Software from steady state values and they were divided by the
corresponding protein size. The F test to compare variances was performed
using GraphPad Prism software.
The new generation SPR analysis was performed using ProteON XPR36 protein
interaction array system (Bio-Rad). The NLC Sensor Chip (Bio-Rad) was
preconditioned according to manufacturerʼs instructions. biotinylated DNA
probes, prepared as described above, at 10 ng/μl were applied vertically at 30 μl/
min for 5 min or until the resonance of each surface reached 550 (+/-40) RU.
One channel was immobilized with 2 mM Biotin to serve as reference cell. 15
serial dilutions of protein samples within 0.01 Kd to 10 Kd range in Buffer B
supplemented with 50 ng/μL poly-dIdC were injected onto each Fc in parallel at
100 μL/min for 2 min. The surfaces were regenerated by 18 sec injection of
Buffer B with 1.5 M KCl (Buffer C).
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Southeastern Blot
!

18 million nuclei from cerebella of WT or KO mice were resuspended in

buffer containing 10 mM Tris pH 8.0 and 150 mM NaCl supplemented with 5mM
CaCl2, 10 mM Na-butyrate, 0.15 mM spermine, 0.5 mM spermidine and Halt
Protease and Phosphatase Inhibitor Cocktail (Pierce). The nuclei were partially
digested by the addition of 100 Kunitz units of Micrococcal Nuclease (NEB) and
aliquots of the reaction were stopped by the addition of excess amount of EGTA
at various time points. The nuclei were then incubated with RNase A/T1 Mix
(Fermentas) lysed in 1% SDS and incubated with Proteinase K for at 37°C for 30
min and 65°C for 30 min. The DNA was extracted with phenol: chloroform:
isoamyl alcohol (25:24:1), precipitated in 70% ethanol and dissolved in TrisEDTA buffer. 0.5-1 µg of DNA was resolved in 2% TAE agarose gel and
transferred to nitrocellulose membrane (Whatman pIc, Maidstone, Kent, UK)
overnight by capillary action in 20X SSC buffer (3M NaCl, 300mM Na-Citrate)
following denaturation in 0.4 M NaOH and 0.6 M NaCl and neutralization in 0.5 M
Tris (pH 7.5) and 1.5 M NaCl of the agarose gel. The membrane was equilibrated
in 6X SSC buffer, air-dried, UV-crosslinked, blocked in 5% fat-free milk in TBS
buffer with 0.2% Tween and incubated with rabbit anti 5hmC antibody (1:500,
Active Motif) or mouse anti 5mC antibody (1:250, Diagenode, Denville NJ, USA)
for 2 hours at room temperature. The membranes were washed for 3 X 5 minutes
and

incubated with a secondary antibody conjugated with horse radish

peroxidase (1:4000, Abcam) for 30 min at room temperature. The blots were
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washed for 3 X 10 minutes, rinsed with water and then reacted with ECL
substrate (Pierce). The signal was detected by exposing reacted blots to
chemiluminescence films (Sigma Aldrich) that were developed in film processor
(Konica Minolta, Osaka, Japan). The gel images from five gels from three
independent experiments were analyzed in ImageJ software. The average
values, standard error of the mean and p values by unpaired t-test were
calculated via GraphPad Prism Software. We refer to this method as
Southeastern blot, since it combines the transfer of an electrophoretically
separated DNA sample onto a membrane as in classical Southern blot technique
with the assaying of chemical modifications as in Eastern blot technique

Fast protein liquid chromatography
!

All fast protein liquid chromatography (FPLC) experiments were performed

in ÄKTAFPLC system (GE Healthcare). A 5mL HiTrap Heparin HP column was
attached to the system after washing the system with MilliQ water and Buffer C ,
and then the upstream of column with running buffer, Buffer B. The flow started at
5 ml/min, 0% B for at least 10 min, such that the column was equilibrated with
ten-fold volumes of running buffer. A 5 mL injection loop was attached and also
equilibrated with 10 volumes of running buffer. The concentrated and precleared
extract was injected manually into the loop, the flow was lowered to 2 mL/min the
flow path was changed to “inject”. 2 mL fractions were collected throughout the
run. After 6 volumes of running buffer passed through the column for 15 min, a
gradient elution process started such that the concentration of Buffer C increased
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from 0% to 100 % in 45 min. The run was stopped when the system was
saturated with 100% buffer C and the fractions were assayed by EMSA.
For size-exclusion chromatography, Superdex 200 HR 10/30 (GE Healthcare)
was used. The system was washed with MilliQ water prior to attaching column,
and column was equilibrated at 0.5 mL/min with 2 volumes of MilliQ water (50
mL) and 2 volumes of Buffer B, adjusted to KCl concentration equivalent to that
of the fractions. A 250 μL injection loop was also attached and washed with 2 mL
of this buffer. The heparin fractions containing the specific activity were then
pooled, concentrated to a total volume of less than 250 μL, precleared and
injected manually. The run was let to proceed at 0.2 mL/min until one volume
buffer B was allowed to flow through. 0.5 mL fractions were collected.
For DNA-affinity column, 1 mL HiTrap Streptavidin HP column was attached to
the system after washing the system with MilliQ water and Buffer Bind & Wash
(BW), containing 5 mM Tris‧HCl pH 7.5, 0.5 mM EDTA pH 8.0 and 1 M NaCl. The
column was equilibrated with ten-fold volumes of buffer BW at 1 mL/min. A 1 mL
injection loop was attached and also equilibrated with 10 volumes of buffer BW.
100 μg biotinylated DNA probe containing C, 5mC or 5hmC (described above)
was injected manually. The binding was allowed to proceed at 0.05 mL/min for 20
min and additional volumes of buffer BW was run through the column. Next, the
column was detached from FPLC system. The system was washed with MilliQ
water and Buffer C, and then the upstream of column with Buffer B. The column
was re-attached and was equilibrated with ten-fold volumes of running buffer at
0.5 ml/min. The size exclusion fractions containing the specific activity were
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pooled, concentrated to a total volume of less than 1mL, precleared and injected
manually, after the injection loop was also equilibrated with 10 volumes of buffer
B. The flow was lowered to 0.4 mL/min the flow path was changed to “inject”. 1
mL fractions were collected throughout the run.

Mass spectrometric identification of isolated proteins.
!

MS analysis was conducted by the Proteomics Resource Center at The

Rockefeller University, New York, NY. Protein bands were reduced and alkylated
and hereafter subjected to in-gel trypsinization following published protocol.
(Shevchenko, Wilm et al. 1996). Post digestion, peptides were extracted and
separated by reversed phase based nano flow liquid chromatography (Dionex,
Boston, MA, USA) connected to an Orbitrap XL mass spectrometer (Thermo,
San Jose, CA, USA). Peptides were subjected to Tandem MS in CID mode.
Tandem MS data were extracted using ProteomeDiscoverer v. 1.3 (Thermo,
Bremen, Germany) and queried against the Rat International Protein Index (IPI
rat) v 3.87 using MASCOT 2.3 (Matrixscience, London, UK). For each identified
protein a rough measure of amount was calculated based on the average area of
the three most abundant peptides (Silva, Gorenstein et al. 2006).
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Animal protocols
All protocols involving animals were approved by the Rockefeller University
Institute Animal Care and Use Committee (protocol number #08114) in
accordance with the National Institute of Health (NIH) guidelines. C57BL/6J mice
an. Mecp2tm1.1Bird hemizygous males were purchased from Jackson Labs at 4
weeks of age. Animals were sacrificed between 7 to 11 weeks of age for
experimentation, unless otherwise indicated. All mice were maintained on a 12 h
light/dark cycle and given ad libitum access to food and water.
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Appendix A
A new method for transient, drug-dependent and cellspecific inhibition of global translation in vivo
A.I. Aim
!

This study tries to examine the requirement for protein synthesis in

specific cell populations in the brain during memory consolidation. To achieve
this, we engineered an endogenous translational inhibitor to become druginducible. We then generated genetically modified mice that carry this
engineered construct under a conditional and ubiquitous promoter, such that the
inhibitor will only be activated in cells that co-express the appropriate
recombinase. In such mouse lines, that express the recombinase in specific cell
populations, we can block protein synthesis temporarily and in a cell-specific
manner. This way, the requirement of protein synthesis in variety of neuronal
subpopulations for different stages and types of memory consolidation can be
systematically tested.

A.II. Background: long term memory and protein synthesis
!

Memory is broadly defined as the capacity of an organism to encode,

store and retrieve information. Since Ebbinghausʼ seminal research in 19th
century (Ebbinghaus 1885), clinical (Scoville and Milner 1957; Squire, Cohen et
al. 1984; Zola-Morgan, Squire et al. 1986), anatomical (Squire, Amaral et al.
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1990; Smith and Jonides 1997), genetic (Jones, Errington et al. 2001; Schmitt,
Deacon et al. 2003) and molecular studies continue to investigate the
involvement of neuroanatomical regions in different stages and types of memory
formation (Gooney, Shaw et al. 2002). The current cortical memory consolidation
scheme starts with the reciprocal strengthening of hippocampal-cortical
connections by the simultaneous activation of these areas (Marr 1970;
Sutherland and McNaughton 2000; Wittenberg, Sullivan et al. 2002). Then, the
intracortical connections strengthen until the memory trace becomes
hippocampus-independent and stable (McClelland, McNaughton et al. 1995;
Graham and Hodges 1997; Dudai 2004).
The first clues that de novo protein synthesis might be necessary for long-term
memory (LTM) formation came about in the 1960s, when chemical protein
synthesis inhibitors blocked LTM leaving the short-term memory (STM) intact
(Flexner, Flexner et al. 1963). Upon LTM-inducing training events, enhanced
translation activity (Martin, Casadio et al. 1997) and activated signaling events
that trigger gene expression (Bartsch, Casadio et al. 1998; Malleret, Haditsch et
al. 2001) were recorded. Although current techniques provide compelling
evidence on mechanisms of memory formation; some are invasive (Alberini
2008; Rudy 2008) and may result in convoluted phenotypes, while noninvasive
imaging techniques do not provide sufficient molecular details. In addition, data in
cell-type resolution is not yet available. By combining a genetic targeting with a
switch by a nontoxic molecule, the strategy presented here offers an alternative,
temporal, noninvasive and cell-specific way to solve questions raised in this field.
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A.III. Background: mammalian protein synthesis
!

Protein synthesis is tightly regulated in mammalian cells at the level of

initiation, that being the first and the rate-limiting step (Kaufman 1994). The 40S
ribosome associates with eukaryotic initiation factors (eIF) 1A and eIF3 and a
ternary complex, made of eIF2, initiator methionyl-tRNA and GTP; and forms the
43S pre-initiation complex. eIF4E, eIF4A and eIF4G together form the capbinding complex, which recruits the ribosome complex on mRNA. 40S ribosome
starts scanning the mRNA until it encounters a start codon, where 60S ribosome
joins in and elongation starts while eIFs are sequentially released (Mathews,
Sonenberg et al. 2007). eIF2 and eIF4E are primary targets for translational
control by cellular mechanisms, in addition to cleavage of eIF4G and other eIFs
by caspases or exogenous proteases (Fig A.1.A) (Holcik and Sonenberg 2005).
Several 4E-binding proteins (4E-BPs) regulate the cap-dependent translation
while phosphorylation of eIF2α by one of the four stress-induced protein kinases
prevents the formation of the ternary complex and inhibits the general protein
synthesis except some mRNAs that carry regulatory sequences as escape
mechanism (Fig A.1.B) (Richter and Sonenberg 2005; Wek, Jiang et al. 2006).

A.IV. Background: effect of protein synthesis inhibitors in brain
!

GCN2 is the major eIF2α-kinase in the brain (Berlanga, Santoyo et al.

1999; Sood, Porter et al. 2000). Gcn2

-/-

mice show mpaired hippocampus-

dependent forms of LTM leaving amygdala-dependent LTM unaffected (CostaMattioli, Gobert et al. 2005). Interestingly these mice have enhanced memory
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with weak training protocols. Similar results were obtained with eIF2α+/S51A mice
that show decrease basal eIF2α phosphorylation (Costa-Mattioli, Gobert et al.
2007). Conversely, Sal003, an inhibitor of eIF2α-dephosphorylation, impairs LTM.
Decreased hippocampal eIF4E phosphorylation was observed in another study
shortly after training (Kelleher Iii, Govindarajan et al. 2004). Two of the eIF4EBPs are inactivated by induction of LTM (Banko, Hou et al. 2006; Gelinas, Banko
et al. 2007). Hippocampal slices from 4E-BP2

-/-

mice had lowered threshold for

LTP. Interestingly in these mice the hippocampus-dependent LTM was impaired
(Banko, Poulin et al. 2005) whereas the cortex-dependent memory was
enhanced (Banko, Merhav et al. 2007).
Among the four eIF2α-kinases (Fig A.1.A), RNA-dependent protein kinase or
protein kinase R (PKR) inhibits global translation in response to viral infection
(Holcik and Sonenberg 2005; Wek, Jiang et al. 2006). There are two ways that
activate PKR: Homodimerization of N-terminal regulatory region upon binding
viral dsRNA and subsequent autophosphorylation of the kinase domain; or the
cleavage of the regulatory domain from the constitutively active kinase domain
(aa 252-551; PKRkin) by virally induced caspases. Dimerization of PKR can be
chemically induced by replacing the N-terminal domain of PKR with a well
established FKBP domain, which can be dimerized via a synthetic ligand,
AP20187. This method can effectively block protein synthesis in cultured cortical
neurons, in parallel with spine growth and long term potentiation (Je, Lu et al.
2009). Yet this study was reproduced in vivo studies.
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A.V. Background: design of site specific cleavage of PKRkin
!

In theory, the constitutively active PKRkin can be engineered to be a

target of a selected protease by replacing an endogenous 13-residue proteasesensitive site (aa 338-350), that separates residues that make up the catalytic
site (Dar, Dever et al. 2005), by the target sequence of that protease, if the
protease does not have other targets in the host organism. The non-structural
protein 3 (NS3) form Hepatitis C Virus (HCV) is a small monomeric protein with
an unusual but well characterized substrate specificity (Steinkuehler, Urbani et al.
1996). It has previously been expressed in mammalian cells without noticeable
toxicity and it is the primary drug target in the HCV (Huang, Murray et al. 2006).
In HVC, NS3 forms a complex with a 14-residue strand of its cofactor, NS4A
protein, and together they process the viral polyprotein into individual
components. A recombinant protease, NS3/4A, was made by fusing the Nterminal proteolytic domain of NS3 to NS4A with a flexible linker.This fusion
stabilizes the structure and the active site, and substantially increases both the
half-life and the enzymatic efficiency (Kim, Morgenstern et al. 1996; Taremi,
Beyer et al. 1998). Among the cleavage sites of NS3 on HCV polyprotein, the
NS5A/B junction (DTEDVVCC`SMSY) shows highest efficiency. In a recent study,
NS3/4A was used as a tool to tag newly synthesized proteins (Lin, Glenn et al.
2008). The authors expressed NS3/4A fused to the C-terminal of the protein of
interest (POI) and N-terminal of a tag, fused via the cleavage site. This way
NS3/4A cleaved itself off from both the POI and the tag. In the presence of the
inhibitor, the POI was expressed as fusion with the tag and NS3/4A. In mice,
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there are two identified targets of NS3 protease, anti-viral response proteins TIRdomain-containing adapter-inducing IFN-β(Li, Sun et al. 2005) and mitochondrial
antiviral signaling protein (Johnson, Owen et al. 2007), meaning that in
transgenic mice with this construct may have compromised immune response.
NS3/4A is an important candidate for new generation drug development. Several
drugs have been designed in the recent years and few even were approved by
Food and Drug Administration as HCV drugs (Romano, Ali et al. 2012). A
product-derived inhibitor of NS3/4A, BILN 2061, with sub-nanomolar inhibition
constant, reduces the viral load below detection limit within 48 hours in clinical
trials (Yee, Farina et al. 2006). The half-life of this complex is estimated in the
order of seconds (Bartenschlager, Lohmann et al. 1995). The development of the
drug was stopped in Phase II trials due to cardiotoxicity when administrated in
high doses over extended periods (Reiser, Hinrichsen et al. 2005).

A.VI. Background: design of the expression system in mice
!

In this method, NS3/4A, PKRkin, engineered to be a target of NS3/4A,

PKRkin*, and eGFP were expressed in a single mouse as a multicistronic
construct (Fig A.2.A), each pair flanking a self-cleaving 14-residue proteinase,
2A, from foot-and-mouth disease virus (FMDV) (Donnelly, Gani et al. 1997). The
cleavage mediated by this protein is shown to take place during translation by
ribosome-skipping (Donnelly, Luke et al. 2001). Once 2A is synthesized it cleaves
itself off from the growing peptide chain fused to the upstream and the translation
of the downstream protein resumes following the cleavage. 2A is shown to
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function exclusively in cis and it has no detectable toxicity. The cleavage
efficiency increases from 80% to 99% when 2A includes its upstream 39 amino
acids from FMDV polyprotein. This protein has been successfully used in several
studies as a tool to make multicistronic constructs (de Felipe, Martin et al. 1999;
de Felipe 2004). Alternatively NS3/4A and PKRkin* could be expressed as a
fusion protein with a flexible linker, allowing proximity of the enzyme to its
substrate and 1:1 ratio of enzyme and its substrate. NS3/4A in fusion with its
substrate has been successfully used in vivo (Lin, Glenn et al. 2008).
In order to make this construct conditionally expressed in specific cell types, a
variation of the well established genetic scheme involving Cre/loxP
recombination was chosen (Sauer 1998). Briefly, in this method, the mice are
double transgenic with a Cre recombinase that can excise a sequence flanked by
13 bp long Cre recognition sites, called loxP, or “floxed”; and with the gene of
interest that is preceded by a floxed “STOP” cassette, made of a selectable
marker followed by an SV40 early polyadenylation signal sequence, a false
translational start and a splice donor signal (Lakso, Sauer et al. 1992). The
Eef1a1 locus, encoding a translation elongation factor, was chosen as a recipient
site for transgenic knock-in since it is ubiquitously expressed at high levels and
shows no phenotype upon deletion of one alleles (Klinakis, Szabolcs et al. 2009).
The final construct was designed of 5ʼ and 3ʼ homology regions of the first intron
of Eef1a1 gene locus, a splice acceptor site, a floxed STOP cassette and and the
multicistronic construct. The rational of the strategy is shown in Fig A.2.B.
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A.VII. Results: NS3/4A cleaves PKRkin* but not PKRkin
!

To test the efficiency of proteolysis in mammalian cells, two NS3/4A target

sequences, junction sequences from NS5A/B (DTEDVVCC`SMSY) or NS4A/B
(DEMEEC`ASHLPY) were inserted into a fusion of eGFP and GST. These were
then expressed in 293T cells in a 2A-multicistronic construct containing NS3/4A.
The day following transfection, when equal amounts of cytosolic extracts were
assayed with anti-GFP antibody the cleavage of the NS5A/B junction sequence
was observed to be the most efficient (Fig A.3.A). This also shows that the 2A
had very high cleavage efficiency, such that the polyprotein was absent in the
blots. We next asked whether the expression of genes depends on their position
in the multicistronic construct. In shuffled constructs, we noticed that the gene at
the first position is always expressed at higher levels than at other positions (Fig
A.3.B. left panel), while other positions did not affect the expression levels (Fig A.
3.B. right panel).
The cells were then transfected with multicistronic construct containing PKRkin*
with NS5A/B junction site. The extracts blotted with an anti-PKR antibody show
that significantly lower PKRkin* levels in the presence of NS3/4A, whereas
PKRkin was not affected (Fig A.3.C). At any concentration tested, BILN 2061 was
able to induce the expression of PKRkin*, but did not affect the levels of PKRkin*
in the absence of NS3 or wild type PKRkin. 1 uM BILN 2061 was applied to cells
at various times and cells were lysed simultaneously. Western blot analysis
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showed that by 3-4 hours the PKR levels plateau (Fig A.3.D) which
phosphorylates its target eIF2α.Cells expressing PKRkin were observed to
remain healthy for at least 3 days.

A.VIII Results: PKRkin* inhibits translation in absence of NS3/4A
!

To test the translation inhibition upon drug administration, the

multicistronic construct with PKRkin*, NS3/4A and eGFP was co-transfected with
a Luciferase gene from firefly, Luc2p. At all concentrations tested, 16 hours after
application of BILN 2061, PKRkin* was able to suppress Luciferase activity by
more than 10-fold compared to a control (Fig A.4.A). PKRkin* had increased
activity with respect to wild-type PKRkin, possibly due to some adaptation or
resistance mechanisms taking place in the cell, including inherent susceptibility
of the wild-type PKRkin to endogenous proteases.
To test the inhibition of global translation, newly synthesized proteins were
metabolically labeled in a medium containing

35S

after starvation. In cells

transfected with PKRkin* and NS3/4A, translation rate was comparable to that of
wild-type cells, whereas in the absence of protease translation rate decreased
substantially (Fig A.4.B,C and D).
Although metabolic labeling is a robust way of assessing translation rates in
cultured cells, when this method is applied in vivo in subpopulations of cells, it is
no longer applicable. This necessitated a cell-specific assay of translation rates.
Therefore we used eGFP/L10A reporter-ribosomal fusion. This way not only the
inhibition of translation can be directly assessed by eGFP levels, but also the
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gene expression profile at different time points and between different mouse lines
can be compared, complementary to the information obtained by inhibition of
translation. We purified RNA from transfected cells with eGFP/L10A as reporter,
using antibodies against eGFP. High quality of RNA was observed in every
sample, except when BILN2061, NS3/4A and PKRkin* were present (Fig A.4.E).,
indicating lack of eGFP/L10A protein.
Since in vivo the effect will vary depending on the cell type this is expressed and
the level it is expressed, we sought to design other constructs with varying
induction levels. To improve kinetics we produced a fusion of NS3/4A/PKRkin*
and added more target sites to other loops of PKR (a-c in Fig A.5.A). To make a
self-inducing system we introduced regulatory sequences of genes that are
upregulated by PKR, such as Atf4, upstream of PKR (Blais, Filipenko et al.
2004). In parallel we also tested the less efficient NS4A/B cleavage site and used
the less active forms of the protease, NS3 alone and a T54A mutant NS3 that
has compromised proteolytic activity (Lin, Glenn et al. 2008). The drug-induced
inhibition of translation by some of these constructs is shown in Fig A.5.A. In the
cells, transfected with the NS3/4A/PKRkin* fusions carrying NS4A/B and NS5A/B
cleavage sites, PKRkin* was efficiently cleaved (Fig A.5.B). These and the
original multicistronic NS3/4A & PKRkin* with NS5A/B site were most suitable for
genetic studies, since the drug-induction was the most efficient.
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A.IX. Results: generation and verification of knockin mice
!

This construct was cloned downstream of a floxed STOP cassette and

targeted to a ubiquitous and high expressing Eef1a1 locus (Fig A.6.A) (Klinakis,
Szabolcs et al. 2009). Knockin mice were generated, clones that were positive in
genotyping were confirmed by Southern blotting (Fig A.6.B). These mice can now
be bred to a mouse line with a specific Cre recombinase expression pattern.
When these mice were bred to Emx1 BAC-Cre mice (Schmidt, Warner-Schmidt
et al. 2012), expected eGFP expression patterns was observed in brain sections
without immunostaining (Fig A.7).
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A.X. Discussion
!

This new way of modifying translation rates in vivo offers many

advantages compared to the pre-existing techniques. First, by using mouse lines
that express Cre recombinase in specific subpopulation, the requirement of
protein translation can be tested cell specifically. Second, applying the drug at
various time points, at various dosages and in specific brain regions the duration,
level and neuroanatomical extent of inhibition can also be regulated. Conditional
mice that carry constructs with different induction characteristics can also offer
additional dosage regulation. Third, since none of the elements that are used in
the system have invasive side effects, the observed effects are likely to be the
direct result of blocking the protein synthesis in the target cell population. Finally,
since the method is reversible and not invasive, a single animal can be tested
over various stages in a behavioral paradigm. In addition, the eGFP /L10A tag
allows direct assessment of gene expression in these cells in comparison to
other tissues or over different time points. This method is devised to test whether
protein synthesis is required in selected cell types for different types of memory
consolidation. However they can be of multipurpose; for example in the case of
tinnitus, ringing in the ears, which might be related to dysfunction in plasticity
(Engineer, Riley et al. 2011).
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A.XI. Materials and Methods:
Chemicals and construction of recombinant plasmids
!

The gene for HCV polyprotein was kindly provided by Dr. Charles Rice.

The 2A gene was kindly provided by Dr. Martin Ryan. The PKR gene was a gift
from Dr. Prerana Shresta and the eGFP/L10A was a gift from Dr Joseph
Dougherty. eGFP and GST proteins were fused via control linker, or the junction
sequences from NS5A/B or NS4A/B (DEMEEC`ASHLPY) by chimeric primers
and overlap extension PCR. PKRkin* was produced the same way. The elements
of the constructs were amplified using Phusion polymerase (NEB) and cloned
into peGFP-N1 vector (Clontech) using appropriate restriction enzymes (NEB).

primer

sequence

PKRkin F

GAAACAAAGTATACTGTGGACAAGAG

PKRkin R

ACATGTGTGTCGTTCATTTTTCTCTG

PKRkin* Rin

GTCCAGGTGTAGCTCATGCTGCAGCACACCACGTCCTCGGTGTC

PKRkin* Fin

GCTGCAGCATGAGCTACACCTGGACCGGCAAGAGCAAAAATAG

2A F

GTCACCGAGTTGCTTTACCGGATGAAG

2A R

CGAGTCCAACCCTGGGCCCTTTTTTTTTAGT

NS3/4A F

GGCAGCGTGGTCATTGTGGGCAGGATC

NS3/4A R

CTATGGAAACCACTATGCGGGGGGC

eGFP-L10A F

CAGCTCCTCGCCCTTGCTCACCAT

eGFP-L10A R

ATACAGACGCTGGGGCTTGCCCATG

PKRkin* mF-in

CGAGATGGAGGAGTGCGCCAGCCACCTGCCCTACAGCAAAAATAGTTCAAG
GTCAAAGAC

PKRkin* mRin

GGTGGCTGGCGCACTCCTCCATCTCGTCACTGGTCTCAGGATCATAATC
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PKRkin* 1-Rin

CTCATGCTACAGCACACCACGTCCTCGGTGTCATATTTAACACGTTTAATAAC
GTAAGTCTTTCCGTCAATTC

PKRkin* 1-Fin

GACGTGGTGTGCTGTAGCATGAGCTACACCTGGACCGGCAACGAGAAGGCG
GAGCGTGAAGTAAAAGCATTG

PKRkin* 2-Rin

GTAGCTCATGCTACAGCACACCACGTCCTCGGTGTCCTCGCCTCTTCTTTTT
TCAATCCATTGTTC

PKRkin* 2-Fin

GTGTGCTGTAGCATGAGCTACACCTGGACCGGCCTAGACAAAGTTTTGGCTT
TGGAACTCTTTG

PKRkin* 3-Rin

GTAGCTCATGCTACAGCACACCACGTCCTCGGTGTCATTTTTCAGAGATGTTA
CAAGTCCAAAGTC

PKRkin* 3-Fin

GTGTGCTGTAGCATGAGCTACACCTGGACCGGCAAGCGAACAAGGAGTAAG
GGAAC

Ns3/4A B-F

ATTACGGCCTACTCCCAACAGACGC

Ns3/4A B-R

CTATGGAAACCACTATGCGGGGGGC

Ns3/4A C-Fin

TCCTGGCGACCTGCGTCAATGGCGTGTGTTGGGC

Ns3/4A C-Rin

GCACCATGATAGACAGCCCAACACACGCCATTG

eGFP F

CAGCTCCTCGCCCTTGCTCACCAT

eGFP R

CTTGTACAGCTCGTCCATGCCGAGAGTGATC

GST F

TCCCCTATACTAGGTTATTGGAAAATTAAGGGC

GST R

ACGCGGAACCAGATCCGATTTTGGAGGATG

Rluc F

GCTTCCAAGGTGTACGACCCCG

Rluc R

CTGCTCGTTCTTCAGCACGCG

Purifications were done using PCR extraction kit (Qiagen). The ligations were
performed with Quick Ligase Kit (NEB) and the products were transformed into
chemically competent TOP10 cells (Invitrogen) that were grown in LB medium
(Sigma) in presence of 35 mg/ml Kanamycin (Sigma). The plasmids were purified
using a Miniprep kit (Qiagen). Every construct was verified by sequencing.
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The plasmid containing the STOP sequence and the Eef1a1 targeting plasmid
were kindly provided by Dr. Apostolos Klinakis. The mammalian expression
constructs were sub-cloned into the gene targeting plasmids as previously
reported (Klinakis, Szabolcs et al. 2009). The final construct was extracted with
phenol: chloroform: isoamyl alcohol (25:24:1), precipitated in 70% ethanol and
dissolved in Tris-EDTA buffer.

Cell culture and transfection
!

Unless otherwise stated the cell culture experiments were done the

following way: 293T cells were grown in a 24-well plate in growth medium
(Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) to have 90%
confluency the day of transfection. They were transfected with 1 ug of a
reference plasmid using 2 uL 293Tfectin (Invitrogen) reagent. The amounts of the
remaining plasmids were adjusted to have the same molarity per well. Cells were
lysed on ice in phosphate-buffered saline supplied with 1% TritonX100 (Sigma)
and inhibitors against proteases (78437, Pierce) phosphatases (78420, Pierce)
and translation machinery (100 ug/ml cycloheximide, Sigma); and the cytosolic
extracts were isolated after precipitating the insoluble fraction. The protein
concentrations were measured using BCA protein assay (Pierce). BILN 2061 was
kindly provided by Boehringer-Ingelheim Inc (Yee, Farina et al. 2006).
The Luciferase assay was performed according to instruction manual after cells
were lysed Dual Luciferase assay kit lysis buffer (Promega).
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Western blotting
!

For Western blotting the extracts were denatured in sample buffer

(Invitrogen) under reducing conditions, separated on a pre-cast Bis-Tris SDS-gel
(Invitrogen) via electrophoresis and transferred on a PVDF-membrane (Biorad).
The membrane was blotted with primary antibodies, anti-GFP (gift of Dr. Brian
Chait), anti-PKR (Abcam), anti-eIF2α (Cell Signaling), anti-phospho-eIF2α (Cell
Signaling) and anti-tubulin (Abcam). The chemiluminescence was detected by
the application of the ECL substrate (Pierce) on the appropriate horse-radishperoxidase-conjugated secondary antibodies.

Metabolic Labeling
To visualize the inhibition of protein synthesis metabolic labeling
experiments were conducted. 20 hours post transfection with 5 ug PKRkin*
construct (with or without NS3/4A) and 10 uL reagent cells in 6-well plate were
labeled with 10 uCi TRAN35S label (MP Biomedicals) for 30 minutes following 30
minutes of starvation before the addition of the label into L-methionine and Lcysteine-free DMEM media (Invitrogen). One well was incubated with
cycloheximide for 10 minutes prior labeling as a control for translation inhibition.
Equal amounts of protein from extracts were separated by electrophoresis and
transferred on a membrane. The membrane was dried in 100% methanol and
analyzed for autoradiography, later it was blotted with antibodies and finally
stained with Coommassie Plus stain (Pierce). Extracts containing equal amounts
of protein were added into scintillation liquid (PerkinElmer) and the radioactivity
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was measured via scintillation counter. The radioactivity was calculated taking
that of the cells in presence of cycloheximide as zero and that of the wild-type
cells as 100%.

Quality control of ribosomal RNA
!

Two custom made mouse anti-GFP antibodies, clones 19C8 and 19F7

(Heiman, Schaefer et al. 2008), were captured on Dynal magnetic beads
(Invitrogen Corporation) coupled with protein L (Pierce). The precleared lysate
from cells was incubated with antibody coupled beads at 4°C with end-over-end
rotation for approximately 16 hours. Beads were subsequently collected on a
magnetic rack, washed three times with high-salt wash buffer (10 mM HEPES
[pH 7.4], 350 mM KCl, 5 mM MgCl2, 1% NP-40, 0.5mM DTT, 100 μg/ml
cycloheximide) and RNA was released and purified using Rneasy Micro Kit
(Qiagen) with in-column DNase digestion. RNA quantity and quality were
determined with a Nanodrop 1000 spectrophotometer (Wilmington) and Agilent
2100 Bioanalyzer using RNA 6000 Pico Chip.

Gene Targeting, Southern Blotting and Genotyping
!

Gene targeting, generation of knockin mice and Southern blotting was

conducted by the Gene Targeting Facility at The Rockefeller University, New
York, NY as previously described (Klinakis, Szabolcs et al. 2009). Following
primers were used for genotyping. The PCRs were performed with ChoiceTaq
(Denville) following manufacturerʼs instructions.
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primer

sequence

β-actin F

GGCTGTATTCCCCTCCATCG

β-actin R

CCAGTTGGTAACAATGCCATGT

eGFP F

GCAGAAGAACGGCATCAAGGT

eGFP R

ACGAACTCCAGCAGGACCATG

GA5 F

GGACCTTTACTTGGTCACGAGGCATGCCGATG

GA5 R

TGCCGGTCCAGGTGTAGCTCATGCTGCAGC

GA4 F

GGACCTTTACTTGGTCACGAGGCATGCCGATG

GA4 R

CAGGTGGCTGGCGCACTCCTCCATCTCGTC

GA F

GGACCTTTACTTGGTCACGAGGCATGCCGATG

GA R

CTAGAAGGCACAGTCGAGGCTGATCAGCGAGCTCG

A2G5 F

CACCATGGGCAAGCCCCAGCGTCTGTATG

A2G5 R

TGCCGGTCCAGGTGTAGCTCATGCTGCAGC

Transgenic mice and visualization of eGFP expression
"

All protocols involving animals were approved by the Rockefeller

University Institute Animal Care and Use Committee (protocol number #09024) in
accordance with the National Institute of Health (NIH) guidelines. All mice were
maintained on a 12 h light/dark cycle and given ad libitum access to food and
water. The Emx1-Cre and Ntsr1-Cre mice were a gift from Dr Eric Schmidt. The
eGFP/L10A expression was detected as previously described (Schmidt, WarnerSchmidt et al. 2012). Mice were deeply anesthetized and transcardially perfused
with PBS followed by 4% paraformaldehyde. Brains were dissected and postfixed
for 1-12 hr at 4°C, cryopreserved in 30% sucrose solution, sectioned on a
freezing microtome (35 μm sections). All sections were imaged on a Zeiss
LSM700 confocal microscope.
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Appendix B
A new drug-inducible Cre recombinase
B.I. Aim
!

Cre recombinase strategy expanded biomedical research using

genetically modified animal models, by introducing spatial control of gene
modifications. However precise temporal control is still not ideal by the currently
available strategies. Here we developed a drug-inducible Cre, that can be used
in a plethora of in vivo gene modifications.

B.II. Background: Cre recombinase and transgenic strategies
!

Our ability to design genetically modified mice made previously impossible

in vivo studies in mammalian organisms possible (Wasserman and DePamphilis
1993). This technology was advanced by the use of recombinase switches that
are utilized to study lethal genes or to isolate phenotypes in adulthood or in
specific cell populations (Sauer 1998)such as those of the brain (Gaveriaux-Ruff
and Kieffer 2007; Gong, Doughty et al. 2007).
Cre site-specific DNA recombinase is a powerful tool for the design of such
switches simply by inclusion of short recombination sites at the site of genetic
modification. Cre is a 38 kDa product of bacteriophage P1 where is catalyzes the
cyclization of P1 plasmid after injection (Sternberg, Sauer et al. 1986), by
recognizing a 34 bp site, called loxP locus. Cre can recognize two loxP sites in
opposite orientation and invert the sequence in between; however when it
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encounters two parallel loxP sites, it excises the sequence flanked by these
(floxed) and ligates them together.
Two strategies were developed that enable Cre to turn on or off genes of interest
(GOI). To turn on genes by Cre, either GOI is reversed between two anti-parallel
loxP sites, or a floxed sequence is cloned upstream of GOI such that the
expression of GOI is disrupted (Gu, Marth et al. 1994). For this purpose, a floxed
“STOP” cassette is used, that is made of a selectable marker followed by an
SV40 early polyadenylation signal sequence, a false translational start and a
splice donor signal (Lakso, Sauer et al. 1992). To turn genes off by Cre, an exon
of GOI can simply be floxed in a way that it does not compromise the expression
or function of the gene in absence of Cre.
Although the use of native gene expression profiles to express Cre, provides
great tissue and cell types specificity, temporal control may not always be
possible. To achieve this, drug responsive promoters have been used (Gossen
and Bujard 1992). Elegant strategies were generated by fusing a mutated human
estrogen receptor (ERT) or progestrone receptor (PRT) to Cre. In absence of
inducer (tamoxifen or mifepristone, respectively) Cre-ERT or PRT is excluded
from the nucleus, however when inducer binds ERT or PRT and then Cre can
penetrate into nucleus (Metzger, Clifford et al. 1995; Brocard, Warot et al. 1997).
Unfortunately these methods showed interference with endogenous signaling
pathways, very high background activities or low efficiencies; or they required
drugs at toxic levels (Brocard, Warot et al. 1997; Kellendonk, Tronche et al. 1999;
Rossant and McMahon 1999; Garcia and Mills 2002).
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An ideal inducible Cre recombinase system has three basic features: (1) no basal
activity in absence of the inducer, (2) nontoxic inducer and (3) inducer that is
effective in low doses. With that in mind we used the rational of the druginducible protein function, as explained in Appendix A (A.I.IV) for making a druginducible Cre. The locations to insert cleavage sites on the Cre recombinase
were selected based on the disordered loops observed on the X-ray structure of
Cre recombinase (Guo, Gopaul et al. 1997); by non-inactivating sites that were
revealed by a previous pentapeptide insertional mutagenesis screen (Petyuk,
McDermott et al. 2004); and by regions where non-homologous loops were found
only in homologs of Cre. The selected sites are shown in Fig B.1.A.
To test the recombination efficiency using one plasmid, we cloned a floxed Luc2p
after start codon and a Renilla Luciferase gene, RLuc, that is not expressed due
to frameshift, such that upon excision of floxed region, RLuc is in-frame and
therefore expressed (Fig B.1.B). We could easily measure the activity of each
Luciferase by using a dual-Luciferase reporter assay (Sherf, Navarro et al. 1996)
and quantify the recombination efficiency by the ratio of two Luciferases.
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B.III. Results: drug-inducible Cre recombinase
!

We have located 8 target sites to introduce the cleavage site as an

insertion. After the initial screen by Luciferase recombination assay, we observed
complete abolishment of Cre activity on some sites (A & D in Fig B.2.A) and no
sign of cleavage on others . By making various combinations of cleavage sites
we managed to generate several double and triple mutants that showed high
induction levels (XY, XG and YGE in Fig B2A). We confirmed our observations in
Western blots, as well (Fig B.2.B).

B.IV. Discussion
!

The drug-inducible Cre described his strategy has a great potential to

improve the currently available inducible recombination strategies. With the
availability of Cre mutants with a variety of background and induction levels, this
technique offers a possibility of making transgenic with desired inducibility of Cre.
This strategy still needs large scale in vivo screens of several transgenic lines,
however the reward will be very useful for temporally controlled in vivo genetic
manipulations.
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B.V. Materials and Methods
!

The gene for Cre recombinase was a gift of Dr. Shiaoching Gong. the

plasmid containing the STOP cassette was from Dr Ana Domingos. For all
protocols, see Materials and Methods from Appendix A.

primer

sequence

Cre F

ATGTCCAATTTACTTACCGTACACC

Cre R

CTAATCGCCATCTTCCAGCAGGCG

Cre X Rin

GTGTAGCTCATGCTGCAGCACACCACGTCCTCGGTGTCATTCAACTTG
CACCATGCCG

Cre X Fin

GCTGCAGCATGAGCTACACCTGGACCGGCAAGAACCGGAAATGGTTTC
CCG

Cre Y Rin

GTGTAGCTCATGCTGCAGCACACCACGTCCTCGGTGTCCAGCCCGGA
CCGACGATG

Cre Y Fin

GCTGCAGCATGAGCTACACCTGGACCGGCAAGCGACCAAGTGACAGC
AATG

Cre A Rin

GCTCATGCTGCAGCACACCACGTCCTCGGTGTCTACTGCCAGACCGC
GCGCCTG

Cre A Fin

GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCGTAAAAACTATCCA
GCAACATTTGGGC

Cre B Rin

GCTCATGCTGCAGCACACCACGTCCTCGGTGTCAGTACGTGAGATATC
TTTAACCCTGATCC

Cre B Fin

GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCAGAATGTTAATCCA
TATTGGCAGAACG

Cre C Rin

GCTCATGCTGCAGCACACCACGTCCTCGGTGTCAGCTACACCAGAGAC
GGAAATCC

Cre C Fin

GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCAACTACCTGTTTTG
CCGGGTCAG

Cre D Rin

GCTCATGCTGCAGCACACCACGTCCTCGGTGTCAGATGGCGCGGCAA
CACC
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Cre D Fin

GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCTCAACTCGCGCCC
TGGAAG

Cre E Rin

GCTCATGCTGCAGCACACCACGTCCTCGGTGTCCTTAGCGCCGTAAAT
CAATCGATG

Cre E Fin

GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCCAGAGATACCTGG
CCTGGTCTG

Cre G Rin

GCTCATGCTGCAGCACACCACGTCCTCGGTGTCGCTATTTTCCATGAGT
GAACGAACCTG

Cre G Fin

GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCCGCTGCCAGGATAT
ACGTAATCTG

Luc2p F

ATGGAAGATGCCAAAAACATTAAGAAG

Luc2p R

TTAGACGTTGATCCTGGCGCTGG
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